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Today, antiretroviral (ARV) therapy is potent, convenient and usually well tolerated, 
capable of reducing human immunodeficiency virus (HIV) blood concentration to undetecta-
ble values within a few weeks from treatment initiation and of inducing a robust and sus-
tained CD4 T-cell gain. Despite these unquestioned successes, the problem is far from being 
solved: even in countries with full access to ARV treatment, life expectancy of people under 
ARV therapy remains lower with respect to that of uninfected people. Furthermore, large 
populations of HIV infected individuals who are not diagnosed remain untreated or enter 
treatment at a very late stage of diseases. Undiagnosed and untreated population represents an 
infected reservoir that increases HIV transmission. 
Patient with Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency 
Syndrome (AIDS) disease face many problems when commencing ARV therapy also called 
as highly active ARV therapy (HAART). In addition to understanding their HIV disease, they 
are prescribed with combination ARV therapy and have a higher risk of developing ADRs. 
Consequently, patients feel that HIV treatment is a burden and turn non-adherent to HAART. 
Understanding about their HIV disease and the importance of HAART in their daily life can 
help patients to be adherent to their HAART by changing their intentional non-adherence be-
havior, negative beliefs and social stigma, which ultimately will improve HAART adherence 
and effectiveness of HIV treatment. Hence, it is important to understand the knowledge, atti-
tude, belief, and practice of HIV patients towards their HIV disease, ARV medications, and 
common adverse effects of ARV along with HAART adherence behavior. One important tool 
for better patient compliance towards HAART is optimizing therapy for minimal side effects 
by therapeutic drug monitoring.  
In the present PhD research work entitled “Traditional and novel therapeutic ap-
proaches for the personalized therapy in HIV patients co-infected with opportunistic infec-
tions and other co-morbidities” we studied the role of therapeutic drug monitoring in 
HAART therapy for personalized patient care.  
The experimental section of the thesis is broadly categories as follows 
1. HPLC UV assay method development for ARV drugs quantification  
2. LC-MS/MS assay method development for ARV drugs quantification 
3. Pharmacokinetics  of ARV drugs dosing at conventional doses 
4. Association between antiretroviral pharmacokinetics and drug-related metabolic disor-
ders  
5. Pharmacokinetic interaction between raltegravir and anti HCV drugs in  an HIV-HCV 
liver transplant recipient 
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The concept of managing pharmacotherapy based on plasma drug concentrations has 
been used for decades in a variety of clinical settings. The interest in therapeutic drug moni-
toring (TDM)[1] of ARV drugs has grown significantly since HAART [2] became a standard 
of care in the clinical practice. Beside adherence to the regimen and diet, drug interactions, 
genetically determined differences in drug distribution and/ or elimination significantly affect 
systemic drug concentration. High inter-individual variability in plasma concentrations of 
most ARV drugs and the lower virologic failure rates and adverse events when optimal con-
centrations are achieved, have already been demonstrated [3]. Thus, TDM can aid optimiza-
tion of ARV therapy.  
In the routine clinical practice TDM of ARV drugs is the method of choice to study 
drug-drug interactions as multiple agents are concomitantly used in HAART regimens. 
Moreover, evidence is also available showing that inadequate plasma drug concentrations can 
favour the development of resistance mutations and endanger present and future treatment 
options. A number of clinical trials has demonstrated that drug serum concentrations are an 
important factor for the development of  response to therapy for HIV [4]. The main goal of 
TDM of ARV drugs is to optimise treatment responses and tolerability, and to minimise 
drug-associated toxicity and resistance. A number of studies in adults suggests that modified 
doses and regimen choices based on TDM achieve targeted ARV drug concentrations which 
are associated with improved clinical response and/or tolerability [5–11]. The application of 
TDM requires, however, the availability of feasible and reliable techniques. 
1.1. Analytical techniques in TDM 
As new drugs are constantly approved and introduced in HAART regimen the need of 
TDM is also growing. Chromatography coupled with various spectrophotometer detectors 
such as ultra violet (UV), photodiode array (PDA) and mass spectrometry (MS) are the in-
struments of choice of the most clinical pharmacology laboratories[12]. Alternatively  immu-
noassays[13] which are commercially available for lot of drugs are  also becoming available 
for TDM of ARV’s.  
a. Immunoassays in TDM 
TDM of clinical agents and drugs of abuse testing are now performed by immunoas-
say methods on automated systems. Most immunoassay methods use specimens without any 
pretreatment and are run on fully automated, continuous, random access systems. The assays 
require very small amounts of sample (mostly <100μL), reagents are stored in the analyser, 
and most analysers have stored calibration curves on the system. In immunoassays, the ana-
lyte is detected by its complexation with a specific binding molecule, which in most cases is 
an analyte-specific antibody (or a pair of specific antibodies)[14]. This reaction is further util-
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ized in various formats and labels, giving a whole series of immunoassay technologies, sys-
tems, and options. With respect to assay design, there are two formats of immunoassays: 
competition and immunometric (commonly referred as “sandwich”)[15]. Competition immu-
noassays work best for analytes with small molecular weight, requiring a single analyte-
specific antibody. In contrast, sandwich immunoassays [16] are mostly used for analytes with 
larger molecular weight, such as proteins or peptides, and use two different specific antibod-
ies.  
Since most TDM immunoassays involve analytes of small molecular size, these as-
says employ the competition format. In this format, the analyte molecules in the specimen 
compete with analyte (or its analogues), labelled with a suitable tag provided in the reagent, 
for a limited number of binding sites provided by, for example, an analyte specific antibody 
(also provided in the reagent). Thus, in these types of assays, the higher the analyte concen-
tration in the sample, the less of label can bind to the antibody to form the conjugate. If the 
bound label provides the signal, which in turn is used to calculate the analyte concentration in 
the sample, the analyte concentration in the specimen is inversely proportional to the signal 
produced. If the free label provides the signal, then signal produced is proportional to the ana-
lyte concentration. The signal is mostly optical—absorbance, fluorescence, or chemilumines-
cence (Figure 1 and Figure 2).  
 
Figure 1.  Competition immunoassays 
 
Figure 2. Sandwich immunoassay 
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There are variations in this basic format. The assays can be homogeneous [17] or het-
erogeneous [18]. In the former, the bound label has different properties than the free label. 
For example, in fluorescent polarisation immunoassay (FPIA) [19] , the free label has differ-
ent Brownian motion than when the relatively small molecular weight (a few hundreds to 
thousand Daltons) label is complexed with a large antibody (140,000 D). This results in dif-
ferent fluorescence polarisation properties of the label, which is utilized to quantify the bound 
label [19].  
In heterogeneous immunoassays [20], on the contrary, the bound label is physically 
separated from the unbound labels, and its signal is measured. The separation is often done 
magnetically, where the reagent analyte (or its analogue) is provided as coupled to paramag-
netic particles (PMP), and the antibody is labelled. Conversely, the antibody may be also 
provided as conjugated to the PMP, and the reagent analyte may carry the label. After separa-
tion and wash, the bound label is reacted with other reagents to generate the signal. This is 
the mechanism occurring in many chemiluminescence immunoassays [21] (CLIA), where the 
label may be a small molecule which generates chemiluminescent signals. The label also may 
be an enzyme [enzyme-linked immunosorbent assay (ELISA)], which generates chemilumi-
nescent, fluorometric, or colorimetric signal. In older immunoassay formats, the labels used 
to be radioactive [radio-immunoassay (RIA)]. But because of safety and waste disposal is-
sues, RIA is rarely used today.  
Even though the immunoassay methods are now widely used, there are few limita-
tions of this technique. Antibody specificity is the major concern of an immunoassay. Many 
endogenous metabolites of the analyte (drug) may have very similar structural recognition 
motif as the analyte itself. There may be other molecules unrelated to the analyte but produc-
ing a recognition motif comparable to that of the analyte. These molecules are generally 
called cross-reactants. When present in the sample, these molecules may produce false results 
(both positive and negative interference) in the relevant immunoassay. Other components in a 
specimen, such as bilirubin, haemoglobin, or lipids, may interfere in the immunoassay by in-
terfering with the assay signal, thus producing incorrect results. A third type of immunoassay 
interference involves endogenous human antibodies in the specimen, which may interfere 
with components of the assay reagent such as the assay antibodies, or the antigen-labels. Such 
interference includes the interference from heterophilic antibodies or various human anti-
animal antibodies [22]. Presently, such methodologies provide poor performance for the es-
timation of ARV drugs concentrations. 
b. Gas–liquid chromatography (GC) 
Gas–liquid chromatography is a separation technique first described in 1952 by James 
and Martin. In most GC column, the stationary phase is a liquid and the mobile phase is an 
inert gas. Typically, the stationary phase has a low vapor pressure so that at column tempera-
Introduction 
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ture it can be considered nonvolatile. Introduction of the capillary column dramatically im-
proved resolution of peaks in GC analysis. Resolution equivalent to several hundred thousand 
theoretical plates is achievable using a fused silica capillary column. Depending on the sta-
tionary phase composition, a GC column may have low polarity, intermediate polarity, or 
high polarity.  
Microprocessor control of oven temperature and automatic sample injection tech-
niques also enhanced both performance and ease of automation of GC technique in clinical 
laboratories. The sensitivity and specificity of GC analysis depends on the choice of detector. 
Mass spectrometry can be used in combination with a GC, and MS is capable of producing a 
mass spectrum of any compound coming out of the column of gas chromatograph. Nitrogen 
phosphorus detector is specific for nitrogen- and phosphorus-containing compounds and is 
very sensitive. Electron capture detector can detect any halogen-containing compounds. 
Flame ionization and thermal conductivity detectors are also used in GC. The major limita-
tion of GC is that this technique can only be applied to volatile substances with relatively low 
molecular weights. Polar compounds cannot be analyzed by this technique. However, a rela-
tively polar compound can be chemically converted to a non-polar compound (derivatisation) 
for analysis by GC.  
c. High-Performance Liquid Chromatography (HPLC) 
Application of GC as a separation technique is limited to volatile molecules. How-
ever, HPLC[23] can be used for separation of both polar and non-polar molecules. Usually, 
derivatisation is not necessary for HPLC analysis. HPLC is based on the principle of liquid–
liquid chromatography where both mobile phase and stationary phase are liquid. LC using 
column was first described in 1941. In normal LC, the stationary phase is polar and the mo-
bile phase (eluting solvent) is non-polar. In reverse phase chromatography, the stationary 
phase is non-polar and the mobile phase is polar. Several detectors can be used for monitor-
ing elution of peaks from HPLC column including UV, PDA, MS, fluorescence detectors, 
conductivity detectors, and refractive index detectors. UV detection is commonly used in 
clinical laboratories although other detection techniques such as fluorescence technique and 
electrochemical detection technique are also common. 
d. Liquid Chromatography- Mass Spectrometry (LC-MS) 
MS when combines with LC offers specificity and selectivity higher than the other 
methods. A Mass Spectrophotometer [24] is capable of analysing charged particle based on 
their mass. A typical mass spectrometer consists of an inlet system, which supplies the pure 
compound (separated from complex biological matrix by GC or HPLC) to the mass spec-
trometer, an ion source, a mass analyser, and a detector. The ion source is responsible for 
fragmentation pattern of the compound of interest in characteristic pattern depending on the 
Introduction 
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functional groups and other structural features of the molecule. The detector plots a chroma-
togram listing all ions generated and separated by their mass to charge ratios as well as abun-
dance. Mass spectrometer is often used as a detector for compounds eluting from a GC or 
column of an HPLC. GC/MS is widely used in clinical toxicology [25] laboratories for detec-
tion and quantification of drugs of abuse in biological matrixes,  such as urine or blood, be-
cause of its specificity, sensitivity, and the availability of larger number of mass spectra in 
standard drug libraries. Coupling of HPLC with MS enables the analysis of thermally labile 
compounds, polar compounds, or compounds with high molecular weights that cannot be 
analysed by GC or a combined GC/MS. Electron ionisation (EI) at 70 eV produces a repro-
ducible mass spectrum, which is a common ion source used in GC/MS analysis of therapeutic 
drugs. The electrospray interface is very common in HPLC/MS analysers used in clinical 
laboratories. The electrospray interface produces single or multiple charged ions directly 
from a solvent system by creating a fine spray of highly charged droplets in the presence of a 
strong electric field with assistance from heat or from pneumatics. The atmospheric pressure 
chemical ionisation interface produces sample ions by charge transfer from reagent ions. The 
reagent ions are produced from solvent vapour of the mobile phase. After producing charged 
particles from the analyte eluting from the column, a mass spectrum is produced by detecting 
these charged particles (positive or negative ion) in the detector of the mass spectrum. The 
major types of mass spectrometric analyzers are quadrupole analyser [26], ion trap analysers 
[27], and time-of-flight analyser [28].  
e. Ultra Performance Liquid Chromatography (UPLC) 
UPLC applies the same principle as HPLC, the difference is the use of sub 2-µm par-
ticle columns in a system holistically designed to maximise the advantages of these columns, 
creating a powerful, robust and reliable solution. UPLC is based on the principal of use of 
stationary phase consisting of particles less than 2 µm while HPLC columns are typically 
filled with particles of 3 to 5 µm. The underlying principles of this evolution are governed by 
the van Deemter equation, which is an empirical formula that describes the relationship be-
tween linear velocity (flow rate) and plate height (HETP or column efficiency)[29]. It was 
found that HETP decreases to a minimum value and then increases with increasing flow rate. 
However, with the 1.7 µm particles used in UPLC, HETP is lowered compared to the larger 
particles and does not increase at higher flow rates. This allow faster separations to be carried 
out on shorter columns and/or with higher flow rates, leading to column increased resolution 
between specific peak pairs and increased peak capacity, defined as the number of peaks that 
can be separated with specified resolution in a given time interval. Efficiency is three times 
greater with 1.7 µm particles compared to 5 µm particles and two times greater compared to 
3.5 µm particles. Resolution is 70% higher than with 5 µm particles and 40% higher than 
with 3.5 µm particles. High speed is obtained because column length with 1.7 µm particles 
can be reduced by a factor of 3 compared to 5 µm particles for the same efficiency, and flow 
rate can be three times higher. This means separations can be nine times faster with equal 
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resolution. Sensitivity increases because less band spreading occurs during migration through 
a column with smaller particles (peak width is less and peak height greater)[30,31]. 
The Van Deemter curve, governed by an equation with three components shows that 
the usable flow range for a good efficiency with a small diameter particles is much greater 
than for larger diameters.  
H=A+B/v+Cv  
where A, B and C are constants 
v is the linear velocity, the carrier gas flow rate 
The A term is independent of velocity and represents "eddy" mixing, its value 
correlating positively with packed column particles’dimension and uniformity.  
The B term represents axial diffusion or the natural diffusion tendency of 
molecules. This effect is diminished at high flow rates and so this term is divided by 
v.  
The C term is due to kinetic resistance to equilibrium in the separation process. The 
kinetic resistance is the time lag involved in moving from the gas phase to the packing sta-
tionary phase and back again. The greater the flow of gas, the more a molecule on the pack-
ing tends to lag behind molecules in the mobile phase. Thus this term is proportional to v and 
shows that it is possible to increase throughput, and thus the speed of analysis without affect-
ing the chromatographic performance. 
1.2. Antiretroviral drugs 
In treating patients infected by HIV, different classes of ARV drugs have been devel-
oped to target various life cycles of the retrovirus. Drug classes include nucleoside reverse 
transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors 
and two new classes, entry inhibitors and integrase strand transfer inhibitors. Table 1 shows a 
summary of the currently available drugs and their respective classes. 
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Table 1. Classification of Antiretroviral drugs  
Sr no Generic Name   
Nucleoside, Nucleotide  
Reverse Transcriptase In-
hibitors (N(t)RTI’s) 
abacavir  (abacavir sulfate, ABC), didanosine  (ddI), 
emtricitabine (FTC), lamivudine  (3TC), stavudine  (d4T), 
tenofovir disoproxil  fumarate  (tenofovir DF, TDF), 
zidovudine  (azidothymidine, AZT, ZDV) 
 
Non-Nucleoside Reverse 
Transcriptase Inhibitors 
(NNRTI’s) 
 
delavirdine  (delavirdine mesylate, DLV), efavirenz  (EFV), 
nevirapine  (extended-release nevirapine, NVP), rilpivirine  
(rilpivirine hydrochloride, RPV), etravirine (ETV) 
 
Protease Inhibitors (PI’s) 
 
atazanavir  (atazanavir sulfate, ATV), darunavir (darunavir 
ethanolate, DRV), fosamprenavir (fosamprenavir calcium, 
FOS-APV, FPV), indinavir  (indinavir sulfate, IDV), 
nelfinavir  (nelfinavir mesylate, NFV), ritonavir  (RTV), 
saquinavir  (saquinavir mesylate, SQV), tipranavir  (TPV), 
lopinavir (LPV), amprenavir (APV) 
 
Fusion Inhibitors 
 
enfuvirtide  (T-20) 
 
Entry Inhibitors 
 
maraviroc  (MVC) 
 
Integrase Inhibitors 
(INSTI’s) 
dolutegravir  (DTG) , elvitegravir (EVG), raltegravir  
(raltegravir potassium, RAL) 
These classes of drugs are used in a combination regimen referred to as the HAART. 
This therapy is extremely effective, and is associated with reduced mortality and has allowed 
HIV infection to become a manageable chronic disease. The HAART regimen involves life-
long treatment and requires constant dose optimization to combat development of viral re-
sistance [32]. Treatment is particularly challenging as each drug has large individual pharma-
cokinetic variability, important adverse effects and considerable potential for drug–drug in-
teractions, and the complex dosing regimen predisposes to non-compliance [33–35]. Because 
of a possible correlation between drug concentrations and efficacy/toxicity, most ARV agents 
may be potential candidates for TDM [36]. Monitoring has been proposed to aid HAART to 
check compliance and individualise dose regimens, as well as to investigate viral resistance 
when integrated with viral DNA genotyping [33,35,37]. 
The practice of treating HIV patients with different types of combination drug thera-
pies has lead to the development of simultaneous HPLC-UV and LC-MS/MS methods. These 
methods have been developed to cover a wide range of possible therapies as each patient may 
be individualized to receive any combination of ARV drugs. 
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The majority of HPLC-UV methods involved protein precipitation and solid phase ex-
traction, HPLC-UV assays are economical and feasible in most of clinical setting but also 
considered as time consuming and less sensitive if compared to mass detection.  LC-MS/MS 
methods have employed protein-precipitation as sample preparation. Although the simplicity 
of this approach enables high-throughput sample preparation, there is the potential for more 
interference from endogenous compounds and matrix effects [38]. Other types of sample 
preparation have therefore been used [39] . Jung and co-workers [40]  used protein precipita-
tion followed by liquid–liquid extraction. Semi-automated liquid–liquid extraction in the 96-
well plate format has also been reported [41]. Notably, Martin et al. [39] published a simulta-
neous method for the determination of 11 ARV in human plasma, using two-dimensional 
chromatography with a total chromatographic run time of 6 min. Briefly, after protein precip-
itation of the plasma sample, the supernatant was injected onto an on-line solid phase extrac-
tion system in which the analytes are firstly retained on an extraction column (Poros), while 
some of the potential interferences are washed to waste. The analytes are then eluted onto an 
analytical column (phenyl-hexyl) for chromatographic separation. The advantages of this ap-
proach are minimal sample handling, relatively clean extracts and moderately high-
throughput. 
Electrospray ionization has been the ion source of choice for most published methods. 
The majority of drugs can be detected by positive ionization. Negative ionization may be re-
quired to obtain the necessary sensitivity for some drugs for example Sylvie Quaranta[42], 
Gehrig AK[43]Jung BH [40] etc. 
1.3. Free Drug fraction determination of ARV drugs for TDM 
Many of the PI’s and NNRTI’s are highly bound to alpha-1-acid glycoprotein [44] 
and variability in free fraction has been reported[45] .Thus the measurement of free (or un-
bound) drug is more appropriate for therapeutic monitoring for these classes of drugs [34]. 
Free ARV drugs can be isolated from plasma using commercially available ultrafiltration de-
vices [45]. The subsequent ultrafiltrate then can be prepare for LC-MS/MS analysis by dilu-
tion [45] or liquid–liquid extraction [46,47] . These methods were successful in the free drug 
analysis of ARV drugs using mass spectrometric conditions similar to those applied to the 
analysis of plasma samples. 
a. Intracellular determination of ARV drugs for TDM 
As the site of action for many ARV drugs is within the infected cell, and intracellular 
accumulation of these drugs may display inter-patient variability, it is argued that the meas-
urement of antiviral concentration in peripheral blood mononuclear cells (PBMC’s) may 
more adequately reflect drug efficacy than plasma [32,48–51]. 
Introduction 
12 
 
For example HIV PI’s exert their action inside cells that are susceptible to HIV infec-
tion. The intracellular pharmacokinetics of these drugs, its relation to the plasma pharmaco-
kinetics, and its relation to drug efficacy and toxicity is therefore an active area of 
research[52–54]. However, determination of the intracellular levels of ARV drugs is an ana-
lytical challenge, because of the small amount of target cells, e.g. PBMC’s, which can be ob-
tained from a patient's blood sample. Approximately one million PBMC’s can be obtained 
from 1–2 mL blood. This amount of PBMC’s has a total intracellular volume of ∼0.4 µL, 
while 500 – 1000 µL plasma can be obtained from that same blood sample. As a conse-
quence, much is known about the plasma pharmacokinetics of HIV PI’s in HIV infected chil-
dren, but no information is available on the intracellular levels of HIV PI’s in this group of 
patients 
For sample preparation normally the plasma layer containing the PBMC’s is treated 
with PBS and lysis buffer to disturb the cell membrane. After centrifugation the supernant 
can be use for further analysis on LC-MS/MS using similar conditions applied to the analysis 
of plasma samples. LC-MS/MS systems are more common for intracellular ARV drugs anal-
ysis as  LC-MS/MS has been shown to provide the required sensitivity to detect low cellular 
ARV concentrations[46,48,53,55,56] .  
b. Active metabolite determination of ARV’s for TDM 
The NRTI’s are prodrugs that require cellular enzymes for conversion to the active 
phosphorylated form [32]. These intracellular phosphorylated metabolites compete with en-
dogenous deoxynucleotide triphosphates for incorporation into the viral DNA. Thus the effi-
cacy of these drugs is related to the cellular concentration of their metabolites. The major dif-
ficulties in measuring these metabolites in PBMC’s are the low intracellular concentrations 
and their polar nature. LC-MS/MS methods for the triphosphate metabolites have been re-
cently reported[57,58]. These methods use standard approaches for peripheral blood mono-
nuclear cell isolation. Chromatography is performed using ion-pairing reagents in order to 
retain the analytes, obtain acceptable peak shape and prevent irreversible adsorption [57,58] . 
Coulier et al.  [57] used negative electrospray ionisation mass spectrometric conditions and 
measured these analytes in the fmol concentration range. Despite the LC-MS/MS technology 
to measure intracellular drug concentrations, there are several limitations and factors relevant 
to TDM purposes: (1) Isolation of peripheral blood mononuclear cell is long and impractical 
for routine analysis; (2) The potential for discrepancy in the cell number when counted under 
a microscope; (3) The possibility of drug–drug interactions at the intracellular level; (4) The 
possibility of analyte binding to intracellular protein and cell membrane [32] .  
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c. Alternative matrix for therapeutic drug monitoring of ARV’s 
Dried blood spot samples have been advocated as an alternative matrces for TDM. 
Dried blood spots allow non-hospital sampling in a resource limited environment and the 
small sampling volume is patient friendly especially for children and neonates. In addition, it 
has reduced risk of HIV transmission and samples can be easily transported or stored[59] . 
The analytes have been found to be stable in dried blood spot for at least seven days at 
30 °C [60], thus allowing transport from regional centers. There are several publication which 
describe simultaneous detection of ARV drug in dried blood spots [55,59–64]. Dried blood 
spots were typically treated with an organic solvent to extract the analytes and direct injection 
on to the LC-MS/MS performed. Mass spectrometric conditions are similar to those used for 
plasma analysis. The measure concentrations in dried blood spots correlated well with that of 
plasma [55,59]. However, some ARV drugs had 50–80% higher concentrations in dried 
blood spots, while other ARV drugs had lower concentration compared to plasma. Hence, 
more investigation into the clinical utility of dried blood spots as an alternative matrix is re-
quired. 
The sensitivity and selectivity of LC-MS/MS has enabled the successful measurement 
of ARV’s in other matrices  such as cerebrospinal fluid,  seminal fluid,  hair and breast milk 
has been reported in the literature[47,65–76]. The measurement of these drugs in cerebrospi-
nal fluid has provided a way to better understand the neurological complications of these 
therapies[47,67], while the investigation of drug pharmacokinetics in seminal fluid and breast 
milk has facilitated understanding of potential ways to prevent HIV transmission [68,74–76]. 
The measurement of ARVs in human hair allows the monitoring of long term drug exposure. 
Huang et al. [71] have reported a LC-MS/MS method capable of measuring 3 ARV drugs in 
human hair. However, the extraction of analytes from hair is rather time consuming and elab-
orate and requires further improvement to be practical for monitoring purposes. 
1.4. Rationale for TDM of ARV’s 
a. Protease Inhibitors (PI’s) 
To date, TDM of PI’s has been a useful tool to optimize HIV-1 treatment, prevent 
drug toxicity, and assess patient compliance[35,77]. PI’s are metabolized mainly by CYP450, 
in particular the CYP3A4 isoenzyme group. With the co-administration of a CYP3A4 inhibi-
tor, RTV or cobicistat  plasma exposure of PI’s can significantly  increase [78,79]. Inducers 
of CYP3A4 may in turn lower PI concentrations, though this effect can be partially reversed 
by the action of the boosters [80]. Due to the potent mechanism-based inhibitory effects of 
RTV on CYP3A4 (50% inhibitory concentration [IC50]: 0.05–1.4 μg/mL), RTV is believed 
to function as an inhibitor for CYP3A4 substrates with chronic administration [81,82]. TPV, 
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DRV, SQV, and LPV all require RTV boosting for clinical use; therefore, the interaction pro-
file of these agents is determined in part by the effect of RTV on individual isoenzymes. 
Many other PI’s (ATV, IDV, FOS-APV) are commonly boosted with RTV to optimize their 
pharmacokinetic profile, simplify their dosing frequency, and improve their side effect pro-
file. Interactions among PI’s can be complex due to varied effects on specific CYP enzymes 
and may result in sub-therapeutic concentrations or additive toxicity.  
RTV co-administration (100 mg twice daily) increased the absolute bioavailability of 
DRV in healthy volunteers from 37% to 82% and produced a 14-fold increase in systemic 
exposure[83] .Administration of DRV/RTV with food increases bioavailability by 30% irre-
spective of whether a low or high-fat meal is administered[84]. A 27% increase in NVP AUC 
and 18–47% increase in Cmin were observed when NVP (200 mg twice daily) was adminis-
tered with two separate formulations of DRV (300 mg by oral solution, 400 mg tablet) boost-
ed with RTV twice daily in HIV-infected patients. A large reduction in DRV AUC was ob-
served when given with LPV/RTV (400/100 mg or 533/133 mg twice daily) in HIV-infected 
patients [85]. 
Co-administration of IDV (800 mg twice daily) and DRV/RTV (400 mg/100 mg 
twice daily) in healthy volunteers results in an increase in IDV AUC and Cmin (23% and 
125%, respectively) and DRV AUC and Cmin (24% and 44%, respectively) compared with 
IDV/RTV (800 mg/100 mg twice daily) alone [86]. RAL and MVC have no significant effect 
on the pharmacokinetics of DRV/RTV.  
b. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI’s) 
NNRTI’s are  inducers of hepatic P-cytochrome 450 (CYP450), isoenzyme 2B6, 2C9 
and 2C19 (EFV [87]), and 3A4 (EFV, NVP, RPV,[88]  and ETV [89]), and their absorption 
and distribution is affected by the drug transporter P-glycoprotein (P-gp)[90]. NNRTI’s, ex-
cept RPV, interact with PI’s[91], MVC[92], analgesics[93], antiarrhythmics[93], 
rifamycins[94], anticoagulants[95], anticonvulsivants[96], antipsychotics[97], 
antidepressants[98], antifungals[99], simeprevir[100], calcium channel blockers[101], contra-
ceptives[102], cytotoxics[103] and many other agents. 
Important food interactions exist with some NNRTI’s. The bioavailability of EFV is 
increased significantly (AUC by 28%, maximum concentration [Cmax] by 79%) with a high-
fat meal (1000 kcal, 500–600 kcal from fat)  resulting in a higher risk for central nervous sys-
tem side effects (e.g., vivid dreams, somnolence)[104].   
ETV exhibits improved bioavailability with food versus fasting, where systemic ex-
posure is reduced by 51%, and should be administered with food [105]. The bioavailability of 
RPV is decreased by 43% to 50% when taken on an empty stomach or with a high-protein 
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nutritional drink (8 grams of fat, 300 kcal) compared with a standard meal (21 grams of fat, 
533 kcal) but is unaffected by a high fat meal (56 grams of fat, 928 kcal) [106]. 
EFV and ETV exhibit a mixed interaction profile, whereas NVP primarily functions 
as an inducer and delavirdine as an inhibitor. EFV is a weak inhibitor of CYP1A2 and 
CYP2D6 in vitro, a strong inhibitor of CYP2C9 and CYP2C19, and an inducer of CYP3A4 
and CYP2B6 [87,105,107]. ETV induces CYP3A4, CYP2B6, and uridine diphosphate 
glucuronosyltransferase (UGT) and inhibits CYP2C9 and CYP2C19 [108]. Drug interaction 
profile of ETV with other ARV drugs has been studied fairly extensively. Serum concentra-
tions for some PI’s are reduced by ETV as a result of CYP3A4 induction. Co-administration 
of ETV and ATV with or without RTV results in reduction in ATV Cmin (38–47%) and in-
creased ETV systemic exposure (30–50%). No significant interaction is noted between 
LPV/RTV and ETV[109]. So at the end ETV should not be administered with unboosted 
PI’s, full-dose RTV, or TPV/RTV but can be safely used with DRV/RTV, LPV/RTV, and 
SQV/RTV.  NVP induces CYP3A4, CYP2B6, CYP2C9, and possibly UGT [110,111].  
RPV exhibits weak induction of CYP3A4 and CYP2C19 at higher doses (150–300 
mg) in vivo, weak induction of CYP1A2 and CYP2B6 in vitro, and is prone to having its me-
tabolism altered by strong CYP3A4 inhibitors [112]. RPV (150 mg daily) increases the Cmax, 
Cmin, and AUC of TDF (300 mg daily) by 21–24% but is not thought to be clinically signifi-
cant  [113]. DRV/RTV (800 mg/100 mg daily) increased RPV AUC and Cmin by 230–280% 
in healthy subjects; no change in DRV or RTV pharmacokinetics was noted[114]. RPV 
pharmacokinetics are similarly increased by LPV/RTV (400 mg/100 mg twice daily) where 
RPV AUC and Cmin are modestly elevated by 52% and 74%, respectively[115]. Further stud-
ies are underway to ascertain the significance of interactions between RPV and other ARV’s.  
c. Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI’s)  
N(t)RTIs are not substrates for, nor do they inhibit or induce, the cytochrome P450 
enzyme system. Therefore, many of the interaction concerns which are common with other 
classes of ARV agents are not a concern with N(t)RTIs. Some mechanisms of potential inter-
actions with N(t)RTIs include competition for renal elimination pathways between concomi-
tant medications and those N(t)RTIs that are exclusively eliminated via the kidneys, and 
changes to or alcohol dehydrogenase pathways which can influence the elimination of ZDV 
and ABC, respectively. TDF has significant interactions to consider with concomitant ARV 
therapy. Specifically, the dose of ddI must be reduced while ATV must be boosted with RTV 
if co-administered with TDF [116].  
d. Entry inhibitors 
MVC, the first in this class also called as CCR5 receptor antagonist is one of the most 
sensitive metabolites of CYP3A4 with no significant involvement of the other CYP450 
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isoenzymes, and has a weak, poorly significant inhibition on CYP1A2, 2B6, 2C8, 2C9, 2C19, 
2D6, 3A4 and 3A5[92]. MVC has a linear pharmacokinetics and therefore, Ctrough can be con-
sidered a reliable indicator of adequate drug dose[117,118]. PI’s and NNRTI’s have a major 
effect on the plasma concentrations of this drug and require halving or doubling the standard 
dose[119]. 
The bioavailability of MVC is reduced by 33% with a high-fat meal and by 20% with 
a low-fat meal [120]. MVC  interaction with NNRTI;s and PI’s is likely due to shared metab-
olism through CYP3A4 and altered p-glycoprotein function[121]. EFV (600 mg daily) reduc-
es the MVC AUC in healthy volunteers and HIV-infected subjects by 51% and 53%, respec-
tively[122,123]. MVC 200 mg twice daily with EFV produced a MVC AUC comparable to 
MVC 100 mg twice daily[122]. MVC systemic exposure is reduced by 53% with ETV [83]. 
No significant change in MVC AUC from historical controls was noted when single-dose 
MVC (300 mg) was combined with NVP (200 mg twice daily) in HIV-infected subjects 
[123]. Co-administration of MVC (300 mg twice daily) with the PI LPV/RTV (400 mg/100 
mg twice daily) in healthy volunteers increased MVC AUC and Cmax by approximately 4-fold 
and 2-fold, respectively [122]. Administration of MVC (100 mg twice daily) with SQV/RTV 
(1000 mg/100 mg twice daily) in healthy subjects increased MVC AUC and Cmax by 9.8-
fold and 4.8-fold, respectively [122]. Inclusion of EFV with either LPV/RTV or SQV/RTV 
yielded sustained increases in MVC AUC (2.5-fold and 5-fold, respectively)[122]. MVC (300 
mg twice daily) with either ATV (400 mg daily) or ATV/RTV (300 mg/100 mg daily) in 
healthy subjects resulted in increased MVC exposure (3.6-fold and 4.9-fold, respectively) 
[122]. In contrast, administration of MVC (150 mg twice daily) with TPV/RTV (500 mg/200 
mg twice daily) produced no clinically significant change in MVC serum concentrations 
(GMRs of 1.02 and 0.86 for MVC AUC or Cmax, respectively) [122]. When MVC (150 mg 
twice daily) was combined with the integrase inhibitor EVG (150 mg daily) and RTV (100 
mg daily) in healthy volunteers, the GMR for MVC AUC was 2.86 [124]. A 37% and 28% 
reduction in RAL AUC and Cmin, respectively, was observed when RAL (400 mg twice daily) 
and MVC (300 mg twice daily) were combined in healthy volunteers, but the clinical signifi-
cance of this is presently unknown due to the wide variability in RAL pharmacokinetics 
[125].  
e. Integrase strand transfer inhibitors (INSTI’s) 
RAL, the first drug to be approved in this class, is primarily glucuronidated by uridine 
glucuronosyl transferase (UGT) 1A1, and has limited drug interactions [126]. Interaction be-
tween RAL and ATV with or without RTV has been evaluated because of the well-
established inhibitory effects of ATV on UGT1A1[127]. RAL however has a high inter- and 
intra-patient pharmacokinetic variability and needs at least a mini-AUC as described above 
for correct assessment [128], as the Ctrough levels may be poorly indicative [129]. ETV de-
creased mean RAL Cmin by 34% in healthy volunteers[130]. Concurrent use of RAL and ETV 
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was associated with incomplete viral suppression in a small case series (n = 4) of HIV-
infected patients, but no clinically significant interaction was noted when ETV and RAL were 
combined with DRV/RTV [131]. An increase in AUC and Cmin (19% and 750%, respective-
ly) is observed when RAL is administered with a high-fat meal; however, RAL may be ad-
ministered with or without food [132]. 
DTG, new drug in this class is also  metabolized via UGT1A1 with a minor contribu-
tion by CYP3A, and is a substrate for P-glycoprotein, with very few dug-drug interactions 
[133], the only relevant one being with metformine, whose exposure results nearly doubled 
by co-administration [134]. There are at present few data on DTG TDM, but it’s pharmacoki-
netics appears to be characterized by low variability [135]. Administration of ATV (400 mg 
daily) or ATV/RTV (300 mg daily) with DTG (30 mg daily) results in modest elevation of 
DTG pharmacokinetics in healthy volunteers (AUC increased by 62–91%, Cmin increased by 
90–121%) but is considered safe [136]. DTG AUC and Cmin are reduced (57% and 75%, re-
spectively) when DTG (50 mg daily) is given with EFV (600 mg daily) but concentrations 
remain 4–5-fold above the protein-adjusted IC50 for wild-type virus [137]. ETV (200 mg 
twice daily) significantly reduces the AUC (71%) and Cmin (88%) of DTG (50 mg daily) in 
healthy volunteers and should not be co-administered unless LPV/RTV or DRV/RTV are also 
included[138]. No interaction is evident between DTG and TDF disoproxil fumarate [139]. 
The drug-drug interaction profile of DTG with MVC and INSTI’s remains to be character-
ized. 
f. Fusion inhibitors (FI’s) 
Enfuvirtide is a synthetic peptide that binds to HIV-1 glycoprotein 41, blocking the 
fusion of viral and cellular membranes [140]. It exhibits a small volume of distribution (5.48 
L), low systemic clearance (1.4 L/h), high plasma protein binding (92%), and high bioavaila-
bility (84.3%). Less than 17% of it is deaminated to a minimally active metabolite, and both 
are primarily eliminated via catabolism to amino acid residues. Following subcutaneous ad-
ministration, T-20 is almost completely absorbed, with a slow and protracted subcutaneous 
absorption, resulting in relatively flat steady-state plasma concentration-time profiles. T-20 
did not influence concentrations of drugs metabolised by CYP3A4, CYP2D6 or N-
acetyltransferase, and had only minimal effects on those metabolised by CYP1A2, CYP2E1 
or CYP2C19 [141]. 
All these drugs therefore have the potential for significant reciprocal drug–drug inter-
actions not to mention those with other co-administered medications, adding to the challenges 
of constructing long-term effective combination ARV regimens. To that endeavour careful 
monitoring of drug exposure is an important component of optimum therapeutic outcome. 
One of the important methods of therapy optimization and personalized patient care system is 
the TDM and the most important tool of TDM is quantitative assays.  
Introduction 
18 
 
Hence we decided to start work with HPLC-UV and LC-MS/MS assay methods devel-
opment and validation for ARV drugs followed by TDM and drug-drug interaction studies.  
1.5. Plan of Work 
a. Development and validation of an HPLC-UV method for the simultaneous quantifica-
tion of nine antiretroviral agents in the plasma of HIV-infected patients 
b. Development and validation of electrospray ionization LC-tandem mass assay for the 
simultaneous measurement of ten antiretroviral agents in human plasma samples 
c. Study of the pharmacokinetics of antiretrovirals  given at conventional doses  in HIV 
patients 
d. Study of the potential correlations between metabolic and kidney disorders and 
atazanavir concentrations in HIV infected patients 
e. Pharmacokinetic interaction study between RAL and the 3D regimen of ombitasvir, 
dasabuvir and paritaprevir/RTV in an HIV-HCV liver transplant recipient 
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2.1. An HPLC-UV method for the simultaneous quantification of nine an-
tiretroviral agents in the plasma of HIV-infected patients 
 
Many methods for the simultaneous quantification of various ARV drugs  using 
HPLC with UV detection have been published [142–149]. Several chromatographic methods 
coupled with tandem mass spectrometry (LC-MS/MS) have been validated to quantify newly 
approved ARV agents like DTG and RPV in plasma samples [150–156]. Methods with mass 
detectors however, require expensive instrumentations and trained, expert personnel; these 
conditions are difficult to satisfy in clinical laboratories of many hospitals. Chromatographic 
analysis coupled with UV detectors (HPLC-UV) represents a cheaper option, more easy to 
adapt to the hospital setting. No HPLC-UV methods for the simultaneous quantification of 
ATV, DTG, DRV, EFV, ETV, RPV, RGV, LPV, and TPV in human plasma have been pub-
lished to date.  
The aim of our study was to develop and validate an HPLC coupled with UV de-
tector analytical method for the simultaneous quantification of the new drugs DTG and RPV 
with the most frequently used seven other ARV drugs in human plasma samples.  
 
2.1.1. Material and Methods 
 
a. Chemicals and reagents 
ATV, DTG, EFV, ETV, LPV, RTG was purchased from Spectra 2000 (Rome, Italy), 
DRV and RPV were kindly provided by Janssen Cilag (Beerse, Belgium), TPV was donated 
by Boehringer and quinoxaline (QX ), used as  internal standard (IS), was purchased from 
Sigma (Milan, Italy). Acetonitrile and methanol (Sigma) were of HPLC grade. Deionised wa-
ter used in all aqueous solutions was obtained from a Milli-Q water purification system (Mil-
lipore, Milan, Italy).  
Stock solutions with a concentration of 1 mg/mL were prepared for ATV, DRV EFV, 
ETV, LPV, RTG, and TPV in methanol.  Stock solutions with a concentration of 1 mg/mL 
were prepared for DTG in methanol/dimethylsulfoxide (98:2) and for RPV in metha-
nol/dimethylsulfoxide (90:10).  A working solution of internal standard (IS) was made with 
QX (7.5 mg/mL) in methanol and stored at 4
0
C until use. 
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Two lots of 6 point of STD and QC’s were made, lot ‘‘A’’ with DTG and EFV with-
out RGV and LPV, and lot ‘‘B’’ with RGV and LPV without DTG and EFV. Calibration 
ranges, from STD 6 to STD 1, and QC concentrations for all drugs are listed in Table 2.  
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Table 2. UV Wavelengths used to Quantify IS and Each Drug , retention time of each drug, relative concentrations (Lots A and B) of 
STD 6 to STD 1 of calibration curves and QCs (QC High, QC Medium, and QC Low) 
Analyte Retention time Wavelengths (nm) Calibration points QC 
STD 1 STD 2 STD 3 STD 4 STD5 STD 6 Low Medium High 
ATV 15.3 260 60 180 600 1800 6000 12000 90 900 2000 
DTG† 5.4 260 20 60 200 800 4000 8000 50 300 2000 
DRV 9.6 260 150 300 900 3000 6000 15000 600 1800 8000 
EFV† 17.1 260 150 300 900 3000 6000 15000 600 1800 8000 
ETV 17.4 305 50 100 500 1000 2000 4000 200 1600 3000 
LPV* 17.4 260 150 300 900 3000 6000 15000 600 1800 8000 
RGV* 5.6 260 40 120 400 1200 4800 9600 80 600 6000 
RPV 13.8 305 20 60 200 400 600 2000 50 300 1000 
TPV 18.7 260 500 1000 5000 10000 20000 40000 2000 16000 30000 
IS 8.6 260 - - - - - - - - - 
†DTG and EFV was only present in lot A due to its coelution with RGV and LPV respectively. 
*LPV and RGV  was only present in lot B due to its coelution with EFV and DTG respectively. 
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c. HPLC-UV apparatus and conditions 
The chromatographic system consisted of an Alliance e2695 Separation Module 
equipped with an online degasser and an automatic injector maintained at 10°C and 2998 
photodiode array detector, set at 260 for ATV, DRV, DTG, EFV, LPV, RTG and TPV and at 
305 nm for ETV and RPV. Data were collected and processed using Empower software for 
HPLC system (Waters, Milan, Italy). 
Separations were performed on an XBridge C18 (4.6 mm X 150 mm, particle size 3.5 
µm; Waters) column equipped with a Sentry (4.6 mm X 10 mm ; Waters) guard column. 
Both columns were maintained at 35°C. Gradient elution was carried out using the mobile 
phase consisted of acetonitrile (solvent A) and 50 mM acetate buffer at pH 4.5 (solvent B) 
and was delivered at a flow rate of 1mL/min (Table 3). The total run time was 25 minutes. 
Table 3. Chromatographic Condition (Gradient)—Mobile Phase: Solvent A 
(CH3COONa 50 mM With Glacial acetic acid, Final pH = 4.5) and Solvent B (HPLC 
Grade Acetonitrile) 
Time Solvent A 
CH3CN 
Solvent B 
50 mM acetate buffer at pH 4.5 
Flow (mL/min) 
0.0 40 60 1 
8.90 40 60 1 
15.00 70 30 1 
18.00 70 30 1 
19.00 40 60 1 
c. Sample preparation 
Patients receiving standard dosing of different ARV drugs underwent blood sampling 
after obtaining their informed consent for the measurement of plasma drug concentrations. 
Blood samples were collected in EDTA tubes and plasma was obtained after centrifugation at 
3000 rpm for 10 minutes at +4
0
C (Sigma 3- 16pk). Plasma samples were then underwent heat 
inactivation procedure for HIV (35 minutes at 58°C). To avoid thawing cycles, each patient 
plasma sample was aliquoted into micro tube of 2 ml and stored at -20
0
C until analysis. On 
the day of analysis an aliquot of 500 µL volume of plasma samples was pipetted into labelled 
disposable polypropylene eppendorf tubes and added with 50 µL of internal standard solu-
tion. The tubes were vortex-mixed for 30s, and then added with 500 µL of 50 mM acetate 
buffer pH 4.5, for protein precipitation. The tubes were vortex-mixed for further 60s and cen-
trifuged at 10,000xg for 10 min at 4°C.   
SPE C18 cartridges were placed on a Vac Elut 20 Manifold (Agilent Technologies) 
and activated with 1 mL of methanol followed by 1 mL of HPLC solvent B before sample 
loading.  Loading was carried out under gravity. Then the cartridges were washed with 500 
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µL of HPLC solvent B, followed by 250 µL of HPLC grade water and then elution was car-
ried out using 1 mL of methanol and acetonitrile solution (90:10, vol/vol). Eluted solution 
were collected into a polypropylene tube and taken to dryness at 50°C in a model Speedvac 
centrifugal evaporator (Bioinstruments, Italy). The residue was re-suspended in 150 µL 
H2O:CH3CN (60:40) centrifuged, filtered and then transferred to polypropylene vials. 30 µL 
were then injected in HPLC. 
d. Specificity and Selectivity 
Interference from endogenous compounds was investigated by analysis of different 
blank plasma samples. Potential interference by ARV drugs concomitantly administered to 
the patients was also evaluated by spiking blank plasma with them.  To test potential con-
comitant medication or xenobiotic interference, plasma from different patients (n=30) given 
different combinations of anti-HIV drugs or antibiotics were analysed.  
e. Accuracy, Precision, Calibration, and Limit of Quantification 
Intraday and interday accuracy and precision were determined by assaying 6 spiked 
plasma samples at 3 different concentrations (QC’s) for all drugs. Accuracy was calculated as 
the percent deviation from the nominal concentration. Interday and intraday precision were 
expressed as the SD at each QC concentration. Each calibration curve was obtained using 6 
calibration points, and the ranges are listed in  Table 2.  Calibration curves were constructed 
by linear least-squares regression (1/x
2
 weighting) of peak height ratios (analyte/IS) versus 
nominal concentrations. The method was considered linear if the coefficient of regression (r
2 
) calculated as mean of 10 curves was equal or better than 0.99  [157].   The calibration 
curves for estimating all the drugs concentrations in unknown samples consisted of six con-
centration of plasma samples. These samples were prepared in every analysis together with a 
blank plasma samples.  
The within-day and between-day coefficient of variation (CV) and the accuracy of the 
method were assessed by calculating daily and overall CV’s and bias values for QC (five rep-
licates at each concentration per analytical run) that were assayed in five separate analytical 
runs. The assay was considered acceptable if CV at each concentration was <15% for both 
within-and between-day variability and the deviation of the mean from the true value was be-
tween ±15% [157]. The lowest identifiable discrete that yielded a signal to noise ratio of 3:1 
and reproducible concentration that showed an imprecision of 20% and accuracy of 73%-
125% for each analyte was accepted as lower limit of quantification (LOQ) and was set as the 
first calibration curve point (Table 4).                                                                                           
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Table 4. Intraday and Interday Precision study of HPLC-UV method 
Within day ATV  DTG DRV ETV EFV RGV RPV  LPV TPV 
LOQ Theoretical concen-
tration (ng/mL) 
 Mean ±SD (ng/mL) 
CV,% 
Accuracy,% 
 
60 
60.3 ± 7.1 
11.73 
100.5 
 
20 
19.9 ± 1.6 
8.1 
99.6 
 
150 
155.2±11.6 
7.50 
103.5 
 
50 
51.7 ± 5.7 
11.0 
103.4 
 
150 
153.2±13.4 
 8.7 
102.1 
 
40 
41.9 ± 5.0 
12.0 
104.8 
 
20 
19.8 ± 0.9 
4.6 
99.2 
 
150 
146 ± 15.53  
10.64 
97.3 
 
500 
529.0±50.14 
9.48, 
105.8 
Low  QC Theoretical con-
centration (ng/mL) 
 Mean ±SD (ng/mL) 
 CV,% 
 Accuracy,% 
 
90  
90.9±6.69 
7.36 
101.0 
 
50 
46.7 ± 2.9 
6.1 
93.5 
 
600 
625.0±76.83 
12.3 
104.2 
 
200 
194.8±25.1 
13.0 
97.0 
 
600  
638.0±50.1 
7.8 
106.3 
 
80 
81.9±7.9 
9.7 
102.4 
 
50 
43.5 0.8 
1.8 
87.1 
 
600 
620.2±65.2 
10.5 
193.4 
 
2000 
2030.4±224.7 
10.0 
101.5 
Medium QC Theoretical  
concentration (ng/mL) 
Mean ±SD (ng/mL) 
 CV,% 
 Accuracy,% 
 
900 
874.5± 64.7 
7.4 
97.2 
 
300 
337.0 ± 21.4 
6.4 
112.4 
 
1800 
1886.6±68.1 
3.6, 
104.8 
 
1600 
1647.5±119.8 
7.3 
103.0 
 
1800  
1834.7±186.2 
10.2 
101.9 
 
600 
620.2 ±51.2 
8.3 
103.4 
 
300 
264.1 ± 6.1 
2.3 
88.0 
 
1800  
1828.3±127.3 
7.0 
101.6 
 
16000 
13962.2±849.4 
6.1 
87.3 
High QC Theoretical   con-
centration (ng/mL) 
Mean ±SD(ng/mL) 
CV,% 
 Accuracy,% 
 
2000 
2169.7± 280.5 
12.93 
108.5 
 
2000 
2215.5 ± 201.3 
9.1 
110.7 
 
8000 
8625.6±530.6 
6.1 
107.8 
 
4000 
4283.2±305.6 
7.1 
107.1 
 
8000  
8177.4±787.0 
9.72 
102.2 
 
6000 
6097.9±662.5 
10.9 
101.6 
 
1000 
935.2 ± 32.4 
3.5 
93.5 
 
8000  
8600.3±585.1 
6.8 
107.5 
 
30000, 
30761.4±1981.4 
6.44 
102.5 
Between day ATV  DTG DRV ETV EFV RGV  RPV LPV TPV 
LOQ Theoretical concen-
tration (ng/mL) 
 Mean ±SD (ng/mL) 
 CV,% 
 Accuracy,% 
 
60 
63.3±6.8 
10.7 
105.5 
 
20 
19.9 ± 0.3 
1.5 
99.8 
 
150 
149.1±15.1 
10.1 
99.4 
 
50 
50.1±5.7 
11.31 
100.2 
 
150 
148.3±12.0 
8.11 
98.9 
 
40 
42.1±4.75 
11.25 
105.3 
 
20 
19.7 ± 0.3 
1.4 
98.5 
 
150 
150.6 ±11.6 
7.7 
100.4 
 
500 
516.5±59.0 
11.4 
3.3 
Low QC Theoretical  con-
centration (ng/mL) 
 Mean ±SD (ng/mL) 
CV,% 
Accuracy,% 
 
90 
99.7± 6.6 
6.7 
110.8 
 
50 
53.7 ± 6.8 
12.7 
107.4 
 
600 
611±15.0 
2.46 
101.8 
 
200 
216.4±31.0  
14.34  
108.2 
 
600  
603.4±53.29 
8.84 
99.43 
 
80 
85.9±8.23 
9.6 
107.4 
 
50 
44.9 ± 4.6 
12.3 
89.7 
 
600 
570±73.4 
12.9 
95.0 
 
2000  
2040.2±148.9 
7.3 
102.0 
Medium QC Theoretical 
concentration(ng/mL) 
 
900 
 
300 
 
1800 
 
1600 
 
1800 
 
600 
 
300 
 
1800 
 
16000 
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 Mean ±SD (ng/mL) 
CV,% 
 Accuracy,% 
964.4 ±57.4 
5.95 
107.1 
340.4 ± 16.1 
4.7 
113.5 
1949.2±52.6 
2.7 
108.3 
1538.2±177.5 
11.5 
96.1 
1850.5±124.7 
6.7  
102.8 
567 ±18.1 
3.2 
94.5 
272.9 ± 30.3 
11.1 
91.0 
1840.5 ±109.9 
6.0 
102.3 
14989.2±2023 
13.5 
93.7 
High  QC Theoretical con-
centration (ng/mL) 
 Mean ±SD (ng/mL) 
CV,% 
Accuracy,% 
 
2000 
1814.8±78.9 
4.35 
90.74 
 
2000 
2182.4 ± 252.5 
11.6 
109.1 
 
8000 
8373.6±828.5 
9.9 
104.7 
 
4000  
4162±297.6 
7.15 
104.0 
 
8000 
8031.6±345.7 
4.3 
99.6 
 
6000 
6120.8±253.6 
4.1 
102.0 
 
1000 
881.5± 88.1 
10.0 
88.2 
 
8000 
8039±1049.1 
13.1 
99.51 
 
30000 
30102.2±1469.4 
4.88 
100.3 
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f. Recovery 
Recovery from plasma, using the extraction procedures, was assessed by comparing 
the peak height ratio obtained from multiple analyses of spiked plasma samples (QC’s) with 
the peak height ratio from direct injections of the same amount of all analytes and IS. The 
assay was accepted if recovery exceeded 60%.  
g. Stability  
Drug stability in plasma samples were studied as per the FDA guidelines [157]. Sta-
bility studies evaluated the stability of all the analytes during sample collection and handling, 
after long-term (intended storage temperature) and short-term (bench top, room temperature) 
storage, and after going through freeze and thaw cycles and the analytical process. Stability 
study also included the evaluation of analyte stability in stock solution. The stability study of 
drugs and IS in plasma extracts included the analytical variability study which was done by 
keeping the samples for overnight at room temperature.  
h. Analysis of Samples from Patients 
The developed method has been routinely use for the TDM of ATV, DRV, DTG, 
ETV, EFV, LPV, RGV, RPV  and TPV  carried out in our routine clinical practice for the op-
timization of HAART therapy of  HIV infected patients .   
2.1.2. Results 
Retention times of all the analytes are shown in Table 2. Retention time of DTG and 
EFV are found to be similar with RGV and LPV respectively. For this reason, 2 different lots 
of STD and QC’s were made. DTG and EFV along with other ARV’s were present in LOT 
A. RGV and LPV along with other ARV’s were present in LOT B.  Representative chroma-
tograms of Std 1 and blank plasma of LOT A, LOT B at 260 nm and ETV and RPV at 305 
nm is shown in Figure 3. Whereas the comparative chromatograms of  Std 6 and Std 1 of 
LOT A and LOT B at 260 nm and ETV and RPV at 305 nm is shown in Figure 4. Mean re-
gression coefficient of determination (r
2
) of all calibration curves was better than 0.99. A lin-
ear through zero regression was chosen due to good linear response for all the drugs up to 
STD 6. 
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Figure 3. Representative chromatograms of Std 1 and blank plasma of Lot A and 
LOT B at 260 nm  and RPV and   ETV at 305 nm 
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Figure 4. Comparative chromatograms of Std 6 and Std 1 of LOT A and LOT B at 
260 nm  and RPV and   ETV at 305 nm 
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a. Specificity and Selectivity 
The assay did not show any significant interference with ARV’s or other concomitant 
drugs administered to the patients at therapeutic doses, excluding the above mentioned over-
lapping of DTG with RGV and EFV with LPV. Five drug-free plasma samples did not show 
any interfering peaks in the retention time windows, considering the specific wavelength for 
each drug . 
b. Accuracy, Precision, and Limit of quantification 
Results of the validation of the methods are listed in Table 4 for all analytes. All ob-
served data [intraday and interday precision as percent relative standard deviation (RSD%) 
and % coefficient of variation (% CV)] were below 15.0%, in line with FDA guidelines 
[157].  A linear response was shown for all drugs up to STD 6. The LLOQ and limit of detec-
tion for each analyte are listed in Table 4. 
c. Recovery 
Multiple aliquots at each of the 3 QC concentrations were assayed; the mean recovery 
of all drugs ranged from 80% and 125%.  
d. Stability 
The stability study of drugs and IS in plasma extracts, kept for 24 hours in the auto-
sampler rack at room temperature, showed a variation of less than 5% for IS and all drugs at 
each concentration. Taking into account the analytical variability, the processed samples were 
stable throughout the HPLC-UV analysis, which was always completed within 24 hours. 
e. Analysis of Samples from Patients  
Our method is regularly applied to the analysis of ARV drugs from the plasma of HIV 
infected blood samples. The developed method was applied for the determination of DRV 
plasma concentration in 371 samples of which 7.8% were found to have levels less the LOQ. 
Measured trough concentrations ranged from 205 to 31488 ng/mL in 342 DRV samples, with 
an inter-individual coefficient of variation (CV%) of 70.6 % (Figure 5, panel A). ATV 
plasma concentration in 1022 samples  were analysed of which 13.5 % were found to have 
concentration less the LOQ. Measured  trough concentrations ranged from 60 to 6144 ng/mL 
in 885 ATV samples, with an inter-individual CV% of  96.8% (Figure 5, panel B). ETV con-
centration found less then LOQ was 8.1 % in 74 patient samples. Measured EFV trough con-
centrations ranged from  53 to 3158 ng/mL in  68 ETV samples, with an inter-individual 
CV% of  85.6% (Figure 5, panel C).  LPV concentration found less then LOQ was 16.7 % in 
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209 patient samples. Measured trough concentrations ranged from 174 to 26125 ng/mL in  
174 LPV samples, with an inter-individual CV% of  66.6% (Figure 5, panel D). EFV con-
centration found less then LOQ was 12.6 % in 207 patient samples. Measured  trough con-
centrations ranged from 454 to 10078 ng/mL in 181 EFV samples, with an inter-individual 
CV% of  65.5% (Figure 5, panel E).  RGV concentration found less then LOQ was 17.1 % in 
408 patient samples. Measured trough concentrations ranged from 42 to 9814 ng/mL in 338 
RGV samples, with an inter-individual CV% of 158.63 (Figure 5, panel F).  TPV concentra-
tion found less then LOQ was 58.3 % in 12 patient samples. Measured EFV trough concen-
trations ranged from 14450 to 28065 ng/mL in  5 TPV samples, with an inter-individual 
CV% of  29.3% (Figure 5, panel G).  Measured RPV trough concentrations ranged from 22 
to 173 ng/mL, with an inter- individual CV% of  48.0% (Figure 5, panel H) in 48 samples 
and no samples found below LOQ level. Measured DTG trough concentrations ranged from 
649 to 2878 ng/mL with an inter-individual variability of 60.8% in 3 samples. The same dis-
tribution was observed also for the other sampling times: DTG concentrations at 1, 2, 3 and 4 
hours after the morning drug intake ranged from 1835 to 3420 ng/mL (CV% 30.4%;), from 
2112 to 5666 ng/mL (CV% 45.1%); from 2836 to 6462 ng/mL (CV% 40.2%) and from 2167 
to 5195 ng/mL (CV% 40.1%), respectively (Figure 5, panel I). 
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Figure 5.Box-plot of DRV (n=342, panel A), ATV (n=885, panel B) , ETV (n=68, 
panel C) , LPV (n=174, panel D), EFV (n=181, panel E), RGV (n=3338, panel F) , 
TPV (n=5, panel G), RPV (n=48, panel H)   plasma trough concentrations and time 
course of DTG plasma concentration (n=15 of 3 patients. Panel I) 
B C 
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2.2. Development and validation of electrospray ionization LC tan-
dem mass assay for the simultaneous measurement of ten antiretrovi-
ral agents in human plasma samples 
This part of the study describes the development and validation of a straightforward 
analytical method for the simultaneous analysis in plasma of the ten ARV agents APV, ATV, 
EFV, RAL, MVC, NVP, NFV,  IDV, SQV and RTV by liquid chromatography coupled with 
tandem triple quadrupole mass spectrometry detection. This method is characterized by a 
very low limit of quantification, greatly below the clinically relevant range of concentrations 
encountered in patients. This method is currently applied in our TDM service for patients’ 
follow-up and for clinical research projects.  
2.2.1. Experimental 
a. Chemicals and reagents 
APV, ATV, EFV, EFV-d4, TDV, MRV-d6, NFV, NVP, RTG, RTV and SQV were 
purchased from Sigma2000 (Rome, Italy), and MVC was obtained from Pfizer. Quinoxaline 
(QX), used as internal standard (IS), was purchased from Sigma (Milan, Italy). Ammonium 
acetate , formic acid, acetonitrile , methanol and all other chemicals (Sigma) were of HPLC 
grade. Deionised water used in all aqueous solutions was obtained from a Milli-Q water puri-
fication system (Millipore, Milan, Italy). Blank plasma used for the assessment of matrix ef-
fect and for the preparation of calibration and control samples was provided by the Lugi sac-
co hospital, Milan, Italy.  Stock solutions with a concentration of 1 mg/mL were prepared for 
all drugs and internal standard (IS) in methanol.  A working solution of internal standard (IS) 
was made with QX (200 ng/mL) in methanol and stored at 4
0
C until use. 
b. Chromatographic and Mass-Spectrometric Conditions 
A Waters Alliance 2695 HPLC separation module (Waters, Milford, Massachusetts, 
U.S.A.) with cooled autosampler and column oven was used to perform the assays. Chroma-
tographic separation was achieved on a Waters XBridge C18. 2.1 mm X 100 mm, particle 
size 3.5 µm HPLC column maintained at 50
0
C. The mobile phases consisted of water + am-
monium acetate 2 mM + formic acid 0.1% (mobile phase A) and methanol + formic acid 
0.1% (mobile phase B). The gradient elution was performed at a flow rate of 0.3 mL/min 
(Table 5). The HPLC was connected to a Quattro Premier XE LC-MS/MS system (Waters, 
Milford, Massachusetts, U.S.A.). Samples were injected into the LC-MS/MS system to de-
termine ARV drug concentrations. Experiments were performed using electrospray ionization 
(ESI) in the positive ion mode except for EFV, performed in the negative ion mode. The pro-
tonated molecules were used as the precursor ion for the MS/MS experiment and the most 
suitable product ion was selected. Drug retention times, parent and daughter ions, cone volt-
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age, and collision energy were optimized for each compound and are listed in Table 6. Data 
were processed using MassLynx software (version 4.1, Waters). 
Table 5.  Chromatographic Condition (Gradient): Buffer A (Ammonium Acetate 2 
mM/Formic Acid 0.1%) and Buffer B (Methanol/Formic Acid 0.1%) 
Time A% B% C% D% Flow Curve 
0.00 90.0 10.0 0.0 0.0 0.300 1 
0.10 90.0 10.0 0.0 0.0 0.300 1 
4.00 10.0 90.0 0.0 0.0 0.300 6 
9.00 0.0 90.0 0.0 0.0 0.300 6 
10.00 0.0 100.0 0.0 0.0 0.300 6 
10.10 0.0 100.0 0.0 0.0 0.500 1 
11.00 0.0 100.0 0.0 0.0 0.500 1 
11.10 90.0 10.0 0.0 0.0 0.300 11 
 
Table 6. Drug Retention Times, Precursor and Product Ions, Cone Voltage, and Collision 
Energy for  all drugs and  Internal Standards ( MVCD6 and  EFVD4 ) by LC-MS/MS in 
Plasma Samples 
Analyte M/Z Cone voltage Collision 
energy 
Retention time 
QX 313.2>246.3 55 40 7.05 
RGV 445.05>108.95 45 28 6.6 (met a 5.5) 
ATV 705.35>335.3 50 30 7.6 
MVC 514.25>280 35 35 5.2 
MVCD6 520.3>280 35 35 5.2 
EFV 314.0>244 30 17 6.7 
EFVD4 318.0>248 30 17 6.7 
APV 506.3>156.0 30 25 6.7 
NVP 267.1>226.1 40 28 5.8 
SQV 671.35>570.4 45 35 7.1 
IDV 614.35>421.35 45 30 6.6 
NFV 568.3–330.2 40 30 6.9 
RTV 721.3>269.25 25 15 7.7 
c. Preparation of Stock Solutions, Calibration Standards, and Quality Control Sam-
ples 
Stock solutions were prepared in methanol to obtain a final concentration of 1 mg/mL, 
for all analyte and internal standard. Aliquots of stock solutions were then stored at -20
0
C for 
no longer than 12 months.  Stock solutions of all analyte except EFV were further diluted in 
methanol to obtain three working solutions with concentrations of 20, 200 and 2,000 ng/mL 
for MCV, 100, 1000 and 15,000 ng/mL  for ATV, 200, 2000 and 20,000 ng/mL  for NVP and 
APV,  100 , 1000, 10,000 ng/mL  for RGV, IDV, SQV, 150, 1500 and 15,000 ng/mL  for 
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RTV, 500, 5000 and 50,000 ng/mL  for NFV. Stock solutions of EFV were further diluted in 
methanol to obtain four working solutions with concentration of 100, 1000, 10000, and 
100,000 ng/mL. Calibration standards were prepared by dilution of various volumes of the 
working solution in blank human plasma as shown in Table 7. Quality control (QC) samples 
were obtained with different stock solutions and were prepared in blank plasma at concentra-
tions of 60, 600, and 4,000 ng/mL for ATV; 80, 800, and 8,000 ng/mL for APV and EFV; 
200, 1000, and 8,000 ng/mL for IDV; 10, 90, and 700 ng/mL for MVC; 100, 1000, and 5,000 
ng/mL for NFV; 80, 800, and 7,000 ng/mL for NVP; 30, 200, and 2,000 ng/mL for RGV; 
100, 500, and 2,000 ng/mL for RTV; 200, 1,000, and 4,000 ng/mL for SQV. Aliquots of the 
QC samples were kept at -20
0
C for a maximum of 12 months. 
Table 7. Standard points of calibration curve of LC-MS/MS method 
STD ATV(µL) 
MVC 
APV 
NVP(µL) 
EFV(µL) RGV(µL) RTV(µL) 
IDV 
SQV 
NFV(µL) 
STD 1 20 25 50 10 10 10 
STD 2 50 50 10 50 20 20 
STD 3 10 10 20 10 50 50 
STD 4 50 20 50 30 10 10 
STD 5 10 50 10 50 20 20 
STD 6 20 10 20 10 50 50 
STD 7 40 20 50 30 10 10 
STD 8 60 50 10 50 20 20 
 
d. Sample Processing 
The extraction method was based on a simple protein precipitation procedure: 200 μL 
of methanol containing the QX (200 ng/ml) were added to 100 μL of plasma sample and 
standard point of calibration curve. 10 µL of deuterated internal standard of MVC and EFV 
were then added to the resultant mix. After vortex mixing for 30 seconds, the samples then 
treated with 600 µL of CH3CN to precipitate out the plasma proteins and vortex again for 30 
sec. Tubes then again centrifuged at 10,000 g for 8 minutes. A 100 mL volume of supernatant 
was then diluted with 200 µL of CH3OH : CH3COONH4  (60 : 40) in another eppendroff  
tubes . Mix was then filtered at 10,000 g for 4 minutes and 20 µL of each sample were inject-
ed onto the analytical column except EFV (40 µL of EFV injected on analytical column) 
e. Linearity 
Calibration standards were prepared and analyzed in 6 replicates in 6 independent 
runs for each compound. Calibration curves were fitted using the quadratic regression and 
applying a 1/X weighting. To obtain acceptable linearity, deviations of the mean calculated 
concentrations over 6 runs had to be within ± 15% of nominal concentrations for the nonzero 
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calibration standards [157]. The limits of quantification (LOQ) were determined in 6 repli-
cates in the same run for each compound. A precision of ± 20% and an accuracy of 80% to 
120% were allowed for the LOQ[157].  
f. Precision and Accuracy 
Intra-assay values were determined by analyzing 6 replicates of each spiked QC sam-
ple in a single assay. Inter-assay values were determined by analyzing 1 QC sample per day 
at each concentration over 6 different days. Intra-assay and inter-assay precisions were ex-
pressed as the percentage coefficient of variation (%CV) at each QC concentration and could 
not exceed  ±15%[157].  Accuracy was calculated as the percent deviation from the nominal 
concentrations and was acceptable if within ±15%[157].  
g. Selectivity and Specificity  
Interferences from endogenous plasma compounds were investigated by analyzing 6 
different blank plasma samples. To investigate the potential interferences of co-medications, 
the ARV drugs concomitantly administered to the patients were assayed by spiking different 
blank plasma containing DRV, ETV, LPV, DTG, RPV and TPV, respectively. 
h. Matrix effect 
Matrix effect was assessed as per the European medicines agency guideline on 
bioanalytical method validation, 2012. Absolute matrix effect was assessed for all analytes 
by comparing the chromatographic peak areas of spiked blank plasma extracts (i.e., after pro-
tein precipitation with methanol and acetonitrile) from 6 different sources with STD2 and 
STD8 to peak areas obtained from the same concentration of analytes in the same composi-
tion of the extract (i.e., 200 μl of methanol + 600 μl of acetonitrile + 200 μl of CH3OH : 
CH3COONH4  ) without plasma. 
Furthermore, matrix effects over an entire chromatographic run were evaluated using 
a post-column infusion of the analytes to ensure that no interfering peaks of the blank plasma 
(n = 7) extract were found at the retention time corresponding to each analytes. The blank 
plasma was extracted and injected into the LC-MS/MS system with concurrent postcolumn 
infusion of analytes. 
i. Stability  
Drug stability in plasma samples were studied as per the FDA guidelines [157]. Sta-
bility studies evaluated the stability of all the analytes during sample collection and handling, 
after long-term (intended storage temperature) and short-term (bench top, room temperature) 
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storage, and after going through freeze and thaw cycles and the analytical process. Stability 
study also included the evaluation of analyte stability in stock solution. The stability study of 
drugs and IS’s in plasma extracts included the analytical variability study which was done by 
keeping the samples for overnight at room temperature.  
j. Analysis of Samples from Patients 
The developed method has been routinely use for the TDM of APV, ATV, EFV, IDV, 
MVC, NFV, NVP, RGV, RTV  and SQV  carried out in our routine clinical practice for the 
optimization of HAART therapy of  HIV infected patients .   
2.2.2. Results  
ARV drugs were detected and quantified overall total run time of 8 minutes. All 
analytes were optimized in terms of cone voltage, collision energy and injection volume prior 
to their quantification by LC-MS/MS. For each selected transition of  APV (m/z 506.3–
156.0), ATV (m/z 705.35–335.3), EFV (m/z 314.0–244), EFVD4 (m/z 318.0–248), IDV (m/z 
614.35–421.35),   MVC (m/z 514.25–280), MVCD6 (m/z 520.3–280), NVP (m/z 267.1–
226.1), NFV (m/z 568.3–330.2),   RGV (m/z 445.05–108.95), SQV (m/z 671.35–570.4), 
RTV (m/z 721.3- 269.25) and QX (m/z 313.2–246.3) the analyte retention times and collision 
energies are shown in Table 6. Representative chromatograms of all analytes STD 1 and 
blank plasma sample of calibration curve are shown in Figure 6 whereas representative 
MRM chromatograms of internal standards: QX , EFV-D4 , and MVC-D6 are shown in Fig-
ure 7.  
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Figure 6. Representative MRM chromatograms of an extracted blank plasma sample and 
an extracted  STD 1  of  ATV (A), APV (B), EFV (C) IDV(D), MVC(E), NFV(F), NVP 
(G),RGV (H), RTV (I), SQV (J) 
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Figure 6. (Continued). 
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Figure 7. Representative MRM chromatograms of internal standards: QX (A), EFV-
D4 (B), and MVC-D6(C) 
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a. Linearity, Precision, and Accuracy 
The assay showed excellent linearity over the studied concentration ranges. The mean 
coefficient of determination (r
2
) of all calibration curves was more than 0.998 across the 6 
validation standard curves. Mean calculated concentrations over 6 runs of all ARV drugs did 
not deviate by more than ± 15% from nominal concentrations for the non-zero calibration 
standards. The LOQ was established at 5 ng/mL for MVC, 10 ng/mL for IDV, RGV, SQV,  
15 ng/mL for RTV, 20 ng/mL for ATV, 50 ng/mL for APV,EFV,NFV,NVP, with a CV% and 
accuracy  ranged from 2.7 % to 14.8 %  and 92 % to 116% respectively (Table 8). The % CV 
and accuracy of the LOQ, for each ARV drug, were within the limits of ± 20% and 80% to 
120% respectively as recommended by the U.S. Food and Drug Administration guidelines 
(Table 8) . LOQ intra-day % CV and accuracy ranged from 2.7 % to 14.0 % and from 92.1% 
to 108.2 % respectively whereas inter-day % CV and accuracy ranged from 7.5 % to 14.6 % 
and from 93.8% to 107.6 % respectively. The results of assay precision and accuracy, as-
sessed at 3 QC concentrations for all ARV agents, are summarized in Table 8.  
 Low QC’s intra-day % CV and accuracy ranged from 8.1 % to 13.1 % and from 87.6 
% to 111.2 % respectively whereas inter-day % CV and accuracy ranged from 5.6 % to 13.57 
% and from 86.4 % to 103.0 % respectively. Mid QC’s intra-day % CV and accuracy ranged 
from 2.53 % to 14.8 % and from 88.3 % to 102.8 % respectively whereas inter-day % CV and 
accuracy ranged from 2.27 % to 14.5 % and from 90.3 % to 107.9 % respectively. High QC’s 
intra-day % CV and accuracy ranged from 4.82 % to 11.4 % and from 87.4 % to 103.0 % re-
spectively whereas inter-day % CV and accuracy ranged from 1.3 % to 10.78 % and from 
89.4 % to 113.1 % respectively. All observed data for the intra-assay and inter-assay were 
less than ± 15.0%. 
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Table 8. Intraday and Interday Precision study of LC-MS/MS method 
Within day ATV APV EFV IDV MVC NFV NVP RGV RTV SQV 
LOQ  
Theoretical concentration (ng/mL) 
Mean ±SD (ng/mL) 
CV,% 
 Accuracy,% 
 
20 
21±3 
13.6 
106.0 
 
50 
51±7 
14.0 
101.6 
 
50 
53 ±7 
13.8 
106.4 
 
10 
11±1 
9.4 
107.2 
 
5 
5±1 
13.2 
97.2 
 
50 
53±8 
14.8 
106.8 
 
50 
53±5 
10.3 
106.0 
 
10 
11±0 
2.7 
108.2 
 
15 
14 ±2 
12.9 
92.1 
 
10 
11±1 
9.8 
106.2 
Low  QC 
Theoretical concentration (ng/mL) 
Mean ±SD (ng/mL) 
CV,% 
Accuracy,% 
 
60 
58.4±7.2 
12.38 
97.3 
 
80 
80.0±8 
10.4 
100.2 
 
80 
88.9±4.6 
5.17 
111.2 
 
200 
187.0±21 
11.1 
93.6 
 
10 
 9.0 ±1 
8.1 
88.8 
 
100 
97.0±9 
9.7 
97.4 
 
80 
70.0±9 
13.1 
87.6 
 
30 
32.4±2.4 
7.31 
107.9 
 
100 
105.0±8.1 
7.74 
105.0 
 
200 
193.0±23 
11.8 
96.5 
Medium QC 
Theoretical  concentration (ng/mL) 
Mean ±SD (ng/mL) 
CV,% 
Accuracy,% 
 
600 
608.6±46.9 
7.7 
101.4 
 
800 
801±86 
10.7 
100.2 
 
800 
742.8±34.2 
4.6 
92.9 
 
1000 
893±58 
6.5 
89.3 
 
90 
92±4 
4.2 
101.7 
 
1000 
922±13.6 
14.8 
92.2 
 
800 
765±65 
8.5 
95.6 
 
200 
186.7±4.7 
2.53 
93.34 
 
500 
513.0±66.0 
12.85 
102.8 
 
1000 
883±69 
7.8 
88.3 
High QC  
Theoretical   concentration (ng/mL) 
Mean ±SD(ng/mL) 
CV,% 
Accuracy,% 
 
4000 
3869.4±366.5 
9.47 
96.7 
 
8000 
8124±811 
10.0 
101.6 
 
8000 
7583.7±233.5 
3.08 
94.8 
 
8000 
8039±496 
6.2 
100.5 
 
700 
727±57 
7.9 
103.8 
 
5000 
4370±497 
11.4 
87.4 
 
7000 
6022±436 
7.2 
96.0 
 
2000 
1969±94.9 
4.82 
98.5 
 
2000 
2059±191.9 
9.31 
103.0 
 
4000 
3966±299 
7.5 
99.1 
Between day ATV APV EFV IDV MVC NFV NVP RGV RTV SQV 
LOQ  
Theoretical concentration (ng/mL) 
Mean ±SD (ng/mL) 
CV,% 
Accuracy,% 
 
20 
21±2 
7.5 
102.7 
 
50 
53±6 
11.1 
105.2 
 
50 
54±8 
14.6 
107.6 
 
10 
10±1 
9.2 
98.8 
 
5 
5±1 
10.2 
102.8 
 
50 
52±6 
12.5 
103.2 
 
50 
47±6 
13.6 
94.4 
 
10 
10±1 
8.8 
102.2 
 
15 
14±1 
8.3 
94.9 
 
10 
9±1 
7.5 
93.8 
Low QC 
Theoretical  concentration (ng/mL) 
Mean ±SD (ng/mL) 
CV,% 
Accuracy,% 
 
60 
54.7±5.4 
9.98 
94.2 
 
80 
76±4 
5.6 
94.4 
 
80 
78.3±10.6 
13.5 
97.9 
 
200 
193±24.4 
12.6 
96.6 
 
10 
8.6±0.6 
6.6 
86.4 
 
100 
97±12.0 
12.37 
97 
 
80 
81±11 
13.9 
101.7 
 
30 
30.5±2.8 
9.28 
101.7 
 
100 
103.0±14.0 
13.57 
103.0 
 
200 
193.6±22.8 
11.78 
96.8 
Medium QC  
Theoretical concentration(ng/mL) 
Mean ±SD (ng/mL) 
CV,%  
Accuracy,% 
 
600 
553.3±50.2 
9.08 
92.2 
 
800 
809±52 
6.4 
101.1 
 
800 
791.2±48.1 
6.07 
98.9 
 
1000 
903.4±24.6 
2.27 
90.3 
 
90 
89.0±13 
14.5 
99.4 
 
1000 
1040±74.3 
7.14 
104.0 
 
800 
864±69 
8.0 
107.9 
 
200 
197.6±16.8 
8.52 
98.5 
 
500 
532.4±67.9 
12.76 
106.5 
 
1000 
938.2±94.4 
10.0 
93.8 
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High  QC  
Theoretical concentration(ng/mL) 
Mean ±SD (ng/mL) 
CV,% 
Accuracy,% 
 
4000 
4006.8±325.7 
8.13 
100.2 
 
8000 
9049±332 
3.7 
113.1 
 
8000 
7815.4±359.0 
4.59 
97.7 
 
8000 
8017.2±536.1 
6.69 
100.2 
 
700 
719±46 
6.4 
102.7 
 
5000 
4468±259 
5.8 
89.4 
 
7000 
6338±85 
1.3 
91.5 
 
2000 
2022±59.6 
2.92 
101.1 
 
2000 
2230.2±240.3 
10.78 
111.5 
 
4000 
3927±423.0 
10.77 
98.2 
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b. Selectivity and Specificity  
After injection of blank plasma or plasma extract containing different ARV drugs , no 
significant interference with ARV agents concomitantly administered to the patients was ob-
served. 
c. Matrix Effect 
Matrix effect of all analytes was evaluated as per the European medicine agency 
guidelines on bioanalytical method validation 2012. A ratio was calculated and typical matrix 
effect observed showed a negligible ion enhancement or no matrix effect for all ARV’s.  
d. Stability 
The stability of PI’s and NNRTI’s at different conditions has been demonstrated pre-
viously in several articles [158–161]. Stability under various conditions for all analytes in-
cluding IS’s (freeze-thaw, heat deactivation, room temperature, solution, and long-term stor-
age stabilities) has also been done [41]. During our validation, all analytes including IS’s was 
stable in plasma after 3 freeze thaw cycles. Stock solutions and QC samples of ARV’s were 
stable at -20
0
C for at least 12 months. Taking into account the analytical variability, the pro-
cessed samples were found to be stable throughout the analysis, which was always completed 
within 24 hours. 
e. Clinical Sample Analysis 
This LC-MS/MS method has been successfully applied for routine TDM in our labor-
atory. We determined trough plasma concentrations with the method reported here using 
samples from patients with HIV-1 treated with drugs mentioned in this method. Box-plot dis-
tribution of APV (n=154, panel A), ATV (n=991, panel B), EFV (n=183, panel C) , MVC 
(n=38, panel D), NVP (n=251, panel E), RGV (n=408, panel F), RTV (n=102, panel G), SQV 
(n=13, panel H) is shown in Figure 8. The developed method was applied for the determina-
tion of NVP plasma concentration in 279 samples of which 10.0 % were found to have levels 
less the LOQ. Measured trough concentrations ranged from 164 to 16896 ng/mL in 251 sam-
ples, with an inter-individual coefficient of variation (CV%) of 45.3 % . ATV plasma concen-
tration in 1021 samples  were analysed of which 2.93 % were found to have concentration 
less the LOQ. Measured  trough concentrations ranged from 20 to 6144 ng/mL in 991 ATV 
samples, with an inter-individual CV% of  107.0 % . APV concentration found less then LOQ 
was 12.9 % in 177 patient samples. Measured APV trough concentrations ranged from 52 to 
11225 ng/mL in 154 APV samples, with an inter-individual CV% of 122.6. RGV concentra-
tion found less then LOQ was 15.4 % in 408 patient samples. Measured trough concentra-
tions ranged from 17 to 9814 ng/mL in 345 RGV samples, with an inter-individual CV% of 
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160.8. RTV concentration found less then LOQ was 12.0 % in 116 patient samples. Measured 
trough concentrations ranged from 15 to 1968 ng/mL in 102 RTV samples, with an inter-
individual CV% of 120.9. MVC concentration found less then LOQ was 17.4 % in 46 patient 
samples. Measured trough concentrations ranged from 11 to 2816 ng/mL in 38 MVC sam-
ples, with an inter-individual CV% of 191.0 %.  EFV concentration found less then LOQ was 
11.6 % in 207 patient samples. Measured EFV trough concentrations ranged from 50 to 
10078 ng/mL in 183 EFV samples, with an inter-individual CV% of 66.6%. SQV concentra-
tion found less then LOQ was 43.5 % in 23 patient samples. Measured EFV trough concen-
trations ranged from 52 to 3433 ng/mL in 13 SQV samples, with an inter-individual CV% of 
87.12 %.   
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Figure 8. Box-plot of APV(n=154, panel A), ATV (n=991, panel B) , EFV (n=183, 
panel C) , MVC (n=38, panel D), NVP (n=251, panel E), RGV (n=408, panel F) , 
RTV (n=102, panel G), SQC (n=13, panel H) 
 
A 
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2.3. A pharmacokinetic viewpoint on conventional antiretrovirals doses and 
possibility of dose reduction  
In this part of the study, experience with TDM of ARV agents carried out as day-by-
day clinical practice for the optimization of drug dosing in HIV-infected patients has been 
described. As mention in the introduction ARV therapy  is not only associated with drug re-
lated side effects but also include drug costs economics which accounts for as much as 60% 
of ARV treatment program costs in several countries [162].  Hence several authors published 
clinical studies and critical reviews advocating for dose reduction of different ARV’s to be 
urgently explored as one of the possible options to help and sustain ART roll-out in develop-
ing countries [163–167].  
ARV drug dosing has not been unchangeable in the past, ZDV (reduced from 1500 to 
500 mg daily) being the clearest example. Indeed ARV doses have often been initially chosen 
on a fairly arbitrary basis: for several ARV drugs, phase 2 data had shown not only no differ-
ence in efficacy between different doses but also better tolerability of lower doses  [168,169]. 
Nonetheless, higher doses were chosen for further trials. 
Stavudine is a particularly interesting example of dose reduction. A meta-analysis of 
dose-ranging studies showed that a 30 mg twice daily dose had the same efficacy of the 40 
mg twice daily dose and a reduced risk of peripheral neuropathy, the drug’s main side effect 
[170]. The dose of this nucleoside analogue was then reduced to 30 mg twice daily. One 
small study showed that stavudine given at 20 mg twice daily can maintain viral suppression 
while reducing lipoatrophy and other mitochondrial adverse effects [171], and this further 
reduced dose could be worthy of a trial.  
EFV, a common component of first-line treatment regimens the world over, is used at 
600 mg once daily. However an initial phase 2 trial showed no difference in efficacy between 
200, 400 or 600 mg once daily dose, combined with ZDV/lamivudine [172] and plasma drug 
levels can be much higher in patients with certain CYP2B6 allelic variants (present mostly in 
Africans) [104], or in individuals with low body weight. The ENCORE 1 trial comparing 
EFV (plus TDF and emtricitabine) at the standard 600 mg once daily dose vs. 400 mg once 
daily for 96 weeks in 630 naive HIV-infected patients started in September 2011 and results 
were available in 2014 [173].  A small study in 33 HIV-infected patients treated with two 
NRTI’s plus EFV at reduced dose has shown no virological failure with a minimum follow-
up of 15 months [174]. 
ATV is a PI currently administered at the dose of either 300 mg with boosted RTV or, 
less frequently, 400 mg once daily. However a pilot study of ATV/RTV at a dose of 200/100 
mg daily in Thai patients showed the same efficacy and plasma ATV drug levels as in Cauca-
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sians on 300/100 mg daily [175], and the same lower dose guided by TDM was effective in 
31 Caucasians[176].  
 DRV was initially used at a 600/100 (RTV) mg twice daily dose in ARV-experienced 
patients. Subsequently, the ARTEMIS [177] ,MONET [178] and ODIN[179] trials have all 
shown the efficacy of a DRV/ RTV 800/100 mg daily dose, which has also a more favorable 
safety profile, in both naive patients and in patients with limited ARV experience. In a small 
number of ARV-highly experienced patients a further reduced dose of DRV/ RTV (600/100 
mg once daily)[180] was tested positively. LPV/RTV is commonly used at the dose of 
400/100 mg twice daily but during its development lower doses have shown similar efficacy 
to the presently used one. In particular the Abbott 720 trial conducted in naive patients evalu-
ated three doses: 200/100 mg twice daily, 400/100 mg twice daily and 400/200 mg twice dai-
ly. The 200/100 dose showed a very good efficacy [168] but the 400/100 mg was chosen for 
phase 3 development. A meta-analysis estimating the effects of LPV dose vs. RTV dose on 
LPV pharmacokinetics in five pharmacokinetic trials of LPV/RTV indicated that a 200/150 
mg twice daily dose of LPV/RTV could maintain very similar LPV plasma levels to the 
standard 400/100 mg dose [78].  
 In a  recent small study in Thai HIV-infected patients, inadequate plasma concentra-
tions were observed with LPV/RTV used at an even lower dose (200/50 mg twice dai-
ly)[181]. However, at week 12, all patients had undetectable plasma HIV-1 RNA [181]. Re-
searchers and clinicians have also used 200/50 mg LPV/RTV twice daily in six HIV-infected 
patients and observed Ctrough of LPV below the suggested minimum concentration of 1000 
ng/ml; however again, all patients continue to have undetectable HIV-RNA levels after 12–
20 months on this low dose [182].  
The goal of this study was to quantify how many HIV-infected patients treated with 
conventional doses of ARV’s had plasma drug trough concentrations – taken as a real-life 
surrogate marker of daily drug exposure – exceeding the upper therapeutic thresholds defined 
by the literature. 
2.3.1. Experimental 
This study is based on a retrospective analysis of routine TDM of ARV concentra-
tions carried out as day-by-day diagnostic service by the Unit of Clinical Pharmacology at the 
Luigi Sacco University Hospital, Milan, Italy, between January 2010 and April 2015. We fo-
cused on the most frequently prescribed drugs, namely ATV, DRV, ETV, LPV, NVP, RAL, 
EFV, MVC and TDF as well as less used agents, such as FOS-APV, SQV, TPV etc . Each 
patient contributed to only one single drug measurement; if more than one assessment is 
available, we considered the first assessment (provided it was collected at a steady state). 
Blood trough samples drawn into EDTA-containing vacutainers were collected from all pa-
tients immediately before the next drug intake (trough samples), that is 24 or 12 h after the 
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last ARV administration in patients given the drug once (q.d.) or twice daily (b.i.d.), respec-
tively. All samples were centrifuged at 3000 g (þ48C), then plasma was separated and stored 
at -20
0
C. Plasma drug concentrations were determined by validated HPLC methods coupled 
either with tandem mass-spectrometric detection or with UV detection. Written informed 
consent with respect to patients’ management was collected at the first outpatient visit. In 
compliance with privacy laws, the patients’ identification code was encrypted before per-
forming the statistical analyses. 
2.3.2. Results  
Measured ARV plasma trough concentrations were stratified according to the thera-
peutic windows of drug concentrations suggested by the DHHS guidelines [183]or by availa-
ble literature, as detailed below. Therapeutic windows considered were 50–180 ng/ml for 
TDF [184–186], 150–800 ng/ml for ATV [183] , 1000–7000 ng/ml for LPV [183,187,188], 
1000–4000 ng/ml for EFV [183,189,190] and 3000– 6000 ng/ml for NVP  [183,191]. For 
other drugs, only the lower therapeutic thresholds of drugs concentrations were retrievable 
from the literature, namely more than 2000 more than 50 and more than 300 ng/ml for DRV 
[192,193], MVC [183]  and ETV [194], respectively. 
As shown in Figure 9 and Table 9, a wide distribution in the plasma trough concen-
trations was observed for most drugs, resulting in different patterns of mean interpatient vari-
ability (expressed as a percentage of coefficient of variation). The developed method was ap-
plied for the determination of DRV plasma concentration in 371 samples of which 7.8 % 
were found to have levels less the LOQ. Measured trough concentrations ranged from 205 to 
31488 ng/mL in 342 DRV , with an inter-individual coefficient of variation (CV%) of 70.6 % 
( Figure 9: panel A, Table 9 ). ATV plasma concentration in 1022 samples  were analysed of 
which 13.5 % were found to have concentration less the LOQ. Measured  trough concentra-
tions ranged from 60 to 6144 ng/mL in 885 ATV samples, with an inter-individual CV% of  
96.8% (Figure 9: panel B, Figure 10,  Table  9).  ETV concentration found less then LOQ 
was 8.1 % in 74 patient samples. Measured ETV trough concentrations ranged from  53 to 
3158 ng/mL in  68 ETV samples, with an inter-individual CV% of  85.6% ( Figure 9 : panel 
C, Table 9).  LPV concentration found less then LOQ was 16.7 % in 209 patient samples. 
Measured trough concentrations ranged from 176 to 26125 ng/mL in  174 LPV samples, with 
an inter-individual CV% of  66.6% (Figure 9 : panel D, Figure 10, Table 9).  EFV concen-
tration found less then LOQ was 12.6 % in 207 patient samples. Measured trough concentra-
tions ranged from 454 to 10078 ng/mL in 183 EFV samples, with an inter-individual CV% of  
65.5% (Figure 9: panel E, Table 9). RGV concentration found less then LOQ was 17.1 % in 
408 patient samples. Measured trough concentrations ranged from 42 to 9814 ng/mL in 338 
RGV samples, with an inter-individual CV% of 158.63 (Figure 9: panel F, Table 9).  TPV 
concentration found less then LOQ was 58.3 % in 12 patient samples. Measured EFV trough 
concentrations ranged from  14450 to 28065 ng/mL in  5 TPV samples, with an inter-
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individual CV% of  29.3% (Figure 9: panel G, Table 9).  Measured RPV trough concentra-
tions ranged from 22 to 173 ng/mL, with an inter- CV%  of  48.0% (Figure 9: panel H, Table 
9) in 48 samples and no samples found below LOQ level.  The developed method was also  
applied for the determination of NVP plasma concentration in 279 samples of which 10.0 % 
were found to have levels less the LOQ. Measured trough concentrations ranged from 164 to 
16896 ng/mL in 250 samples, with an inter-individual coefficient of variation (CV%) of 45.3 
% (Figure 9 : panel I, Figure 10, Table 9). APV concentration found less then LOQ was 
12.9 % in 177 patient samples. Measured APV trough concentrations ranged from 52 to 
11225 ng/mL in 154 APV samples, with an inter-individual CV% of 122.6 (Figure 9: panel 
J, Table 9). RTV concentration found less then LOQ was 12.0 % in 116 patient samples. 
Measured trough concentrations ranged from 15 to 1968 ng/mL in 102 RTV samples, with an 
inter-individual CV% of 120.9 (Figure 9 : panel K, Table 9).  MVC concentration found less 
then LOQ was 17.4 % in 46 patient samples. Measured trough concentrations ranged from 11 
to 2816 ng/mL in 38 MVC samples, with an inter-individual CV% of 191.0 % (Figure 9: 
panel L, Table 9).  SQV concentration found less then LOQ was 43.5 % in 23 patient sam-
ples. Measured SQV trough concentrations ranged from 52 to 3433 ng/mL in 13 SQV sam-
ples, with an inter-individual CV% of  87.12 %  (Figure 9 : panel M, Table 9)  .  Measured 
DTG trough concentrations ranged from 649 to 2878 ng/mL with an inter-individual variabil-
ity of 60.8% in 3 samples. The same distribution was observed also for the other sampling 
times: DTG concentrations at 1, 2, 3 and 4 hours after the morning drug intake ranged from 
1835 to 3420 ng/mL (CV% 30.4%;), from 2112 to 5666 ng/mL (CV% 45.1%); from 2836 to 
6462 ng/mL (CV% 40.2%) and from 2167 to 5195 ng/mL (CV% 40.1%), respectively (Fig-
ure 9 : panel N, Table 9). 
Table 9. ARV’S plasma distribution 
Sr 
no 
Analyte Total Below 
LOQ 
Above 
LOQ 
CV% Concentration 
range 
Assay 
Method 
1 DRV 371 29(7.8%) 342 70.6 205-31488 HPLC-UV 
2 ATV 1022 (13.5%) 885 96.8 60-6144 HPLC-UV 
3 ETV 74 (8.1%) 68 85.6 53-3158 HPLC-UV 
4 LPV 209 (16.7%) 174 66.6 176-26125 HPLC-UV 
5 EFV 207 (12.6%) 183 65.5 454-10078 HPLC-UV 
6 RGV 408 (17.1%) 338 158.6 42-9814 HPLC-UV 
7 TPV 12 (58.3%) 5 29.3 14450-28065 HPLC-UV 
8 RPV 48 (0.0 %) 48 48.0 22-173 HPLC-UV 
9 NVP 279 (10.0%) 250 45.3 164-16896 HPLC-UV  
10 APV 177 (12.9%) 154 122.6 52-11225 LC-MS/MS 
11 RTV 116 (12.0%) 102 120.9 15-1968 LC-MS/MS 
12 MVC 46 (17.4%) 38 191.0 11-2816 LC-MS/MS 
13 SQV 23 (43.5%) 13 87.12 52-3433 LC-MS/MS 
14 DTG Cthrough 3 (0.0 %) 3 60.8 649-2878 HPLC-UV 
 DTG 1 hr 3 (0.0 %) 3 30.4 1835-3428 HPLC-UV 
 DTG 2 hr 3 (0.0 %) 3 45.1 2112-5666 HPLC-UV 
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 DTG 3 hr 3 (0.0 %) 3 40.2 2836-6462 HPLC-UV 
 DTG 4 hr 3 (0.0 %) 3 40.1 2167-5198 HPLC-UV 
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Figure 9. Box-plot of DRV (n=342), ATV (n=885), ETV (n=68), LPV (176), EFV  
(n=183),  RGV (n=338), TPV (n=5), RPV (n=48), NVP (n=251), APV(n=153), EFV 
(n=183, panel C) , RTV (n=102),  MVC (n=38), SQC (n=13), DTG (n=3)  
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Figure 9. (Continued). 
 
Figure 10. Plasma distribution of ATV, LPV and NVP 
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2.4. Metabolic and kidney disorders correlate with high atazanavir concen-
trations in HIV infected patients 
RTV-boosted ATV (ATV/r) is one of the PI’s selected as the preferred choices in the 
American Department of Health and Human Services (DHHS) and European guidelines for 
the initial treatment of patients infected with human immunodeficiency virus-1 (HIV-1) 
[178,183]. This drug is relatively well tolerated in most patients; however, side effects includ-
ing hyperbilirubinemia, which may result in visible jaundice or scleral icterus, dyslipidemias, 
nephrolithiasis and cholelithiasis have been reported in the medium and long term [195–198]. 
RTV enhanced ATV concentrations and improved virologic activity more than unboosted 
ATV [199] . Nevertheless, unboosted ATV may be selected for some patients because it has 
fewer gastrointestinal adverse effects, less hyperbilirubinemia and less impact on lipid pro-
files than ATV/r. TDM of ATV plasma trough concentrations is adopted for the routine man-
agement of patients only in a minority of centre’s worldwide. However, considerable inter-
individual variability has been observed in plasma concentrations of ATV (Table 9) after 
standard dosing, mainly related to drug-to-drug interactions and inherited differences in the 
hepatic metabolism [200–204]. Significant correlations have been reported between plasma 
ATV trough concentrations and clinical outcome. In treatment-experienced as well as naive 
HIV patients the highest probability of achieving undetectable viral load has been associated 
with ATV plasma concentrations >150 ng/mL [203–205]. Accordingly, this threshold con-
centration is currently recommended by international guidelines for the optimal management 
of patients on ATV-based ARV regimens [183]. More scanty data are available concerning 
the relationships between ATV exposure and toxicity. A threshold ATV concentration of 800 
ng/mL has been proposed as a risk factor for hyperbilirubinemia [206,207], whereas no spe-
cific associations have been reported for other ATV-related complications. 
In the present study we sought to: I) assess the distribution of ATV plasma trough 
concentrations in HIV-infected patients according to drug dosage and II) verify a direct asso-
ciation between ATV plasma concentration and the degree of hyperbilirubinemia. As an ex-
ploratory analysis we also investigated the potential relationship between ATV concentra-
tions and other drug-related adverse events (nephrolithiasis and dyslipidemia). 
 
2.4.1. Experimental 
a. Study population 
Male and female HIV-infected patients on ATV-based ARV therapy who underwent 
TDM of ATV concentrations referring to the Department of Infectious Diseases at Luigi Sac-
co University Hospital, Milan, Italy were enrolled in the present study. Paediatric subjects, 
patients with severe hepatic impairment (defined as Child-Pugh Class B or C) or with history 
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of kidney diseases (including previous episodes of nephrolitiasis before initiation of ATV) 
were excluded from the present study. Written informed consent to patients’ management 
(that is consent for diagnostic evaluations, drug administration and all other medical proce-
dures/interventions performed exclusively for routine treatment purposes) was collected to 
the first outpatient visit. Patients provided also written informed consent for their records 
(anonymized) to be used for future research purpose. In compliance with privacy laws, the 
patients’ identification code was encrypted before performing the statistical analyses. Given 
the retrospective observational nature of the present investigation, no formal approval from 
the local ethics committee was required according to the legislation of the national drug 
agency. 
Adherence of patients to therapy was verified through direct questioning during every 
outpatient visits. Data on self-reporting adherence were matched with data from our Pharma-
cy Department in order to verify that patients have accepted the package with the ARV’s 
dose required to fully cover the time between two visits. Only patients with high adherence to 
ARV medications (above 95% of the doses) were considered. 
 
b. Study design 
This study is based on a retrospective analysis of routine TDM of ATV carried out as 
day-by-day clinical practice for the optimisation of drug dosing in HIV-infected patients be-
tween January 2010 and May 2013. HIV-infected patients treated with ATV for at least three 
months and with one assessment of ATV plasma trough concentrations were included. ATV 
plasma trough concentrations were stratified as below, within or above the therapeutic win-
dow, which was set at 150–800 ng/mL according to the available literature[206,207]  
Clinical information on ATV-related complications were recorded in each patient as 
follows. Hyperbilirubinaemia was scored from grade 0 to grade 4 in accordance with the 
AIDS Clinical Trials Group Guidelines for total bilirubin levels [208]: grade 0 (<1.3 mg/dL); 
grade 1 (1.3–1.9 mg/dL); grade 2 (1.9–3.1 mg/dL); grade 3 (3.1–6.1 mg/dL); and grade 4 
(>6.1 mg/dL). Patients with the homozygous UGT1A1*28 genotype were excluded from the 
analysis (higher risk to experience hyperbilirubinemia irrespective of ATV plasma concentra-
tions). Dyslipidemia was defined by the concomitant presence of all these conditions: 1) total 
cholesterol >200 mg/dL or serum triglycerides >180 mg/dL; 2) at least a 20% increase in se-
rum cholesterol or serum triglyceride levels compared to baseline; 3) normal serum lipid lev-
els at the last visit before starting ATV. Nephrolitiasis was defined as episode of acute flank 
pain plus one of the following: 1) new-onset hematuria confirmed by urine analysis, 2) doc-
umented presence of stones or radiological findings suggestive of renal stones 3) stone pas-
sage confirmed by either the patient or attending physician; in the absence of urinary oxalate 
or urate crystals and with normal value of serum uric acid. Patients with history of 
nephrolitiasis before starting treatment with ATV were not included in the present study. 
Experimental and Results 
56 
 
c. Pharmacokinetic evaluations 
Blood trough samples drawn into EDTA-containing vacutainers were collected from 
all patients immediately before the next drug intake, that is 24h or 12h after the last ATV ad-
ministration in patients given the drug qd or bid, respectively (a time window of ± 30 min 
was directly verified by the nurse staff and considered as acceptable). All samples were cen-
trifuged at 3000 g (+4°C), then plasma was separated and stored at -20°C. Plasma ATV con-
centrations were determined by a validated HPLC method coupled with tandem mass-
spectrometric detection (LC-MS/MS) (Section 3.3). Briefly, 100 microL of plasma sample 
was extracted by protein precipitation with acetonitrile. After centrifugation an aliquot of the 
supernatant was analysed by the LC-MS/MS system consisting in a Waters Alliance 2695 
coupled with a Quattro Premier XE triple quadrupole (Waters, Italy). Chromatographic sepa-
ration was performed under gradient conditions on a reversed phase C18 column (Xbridge, 
2.1X100 mm 3.5 microm particle sizes, Waters, Milan, Italy) maintained at 50°C. Mass-
spectrometric analysis was performed in positive electron spray ionisation mode. For quanti-
fication, multiple-reaction monitoring (MRM) mode was applied to monitor the transitions 
from the precursor ion (M+H)+ to the product ion (m/z 705.35 to m/z 335.3 for ATV). The 
method was linear over the ATV concentration ranges of 20 to 9000 ng/mL. The lower limit 
of quantification of the method set at 20 ng/mL. Between and within-day imprecision and 
inaccuracy were less than 15%, as requested by Consensus Guidelines on Bioanalytical 
Method Validations [157].  
d. Statistical analyses 
Results were given as mean (± standard deviation) or median (plus interquartile 
range) according to distribution of the data based on results of the Kolmogorov-Smirnov 
normality test. ATV plasma trough concentrations were stratified according to drug dosage 
(ATV dose, frequency of daily drug administration and concomitant RTV use) and to thera-
peutic window (set at 150–800 ng/mL). All comparisons between two groups were carried 
out using the unpaired t test or Mann-Whitney test, whereas the ANOVA or Kruskall-Wallis 
tests were considered when comparing more than 2 groups, according to the distribution of 
the data. 
The independent association between plasma ATV concentrations and dyslipidemia 
was assessed by means of uni- and multi-variate regression analyses using the event (toxicity 
yes or no) as dichotomic dependent variable and as independent covariates clinical, demo-
graphic and pharmacologic data that resulted significantly associated with the event in the 
univariate models (MEDCALC, Software). A p value of less than 0.05 was considered as sta-
tistically significant. 
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2.4.2. Results  
a. Patients’ characteristics 
Two-hundred forty HIV-infected adult patients were included in the present study. 
Demographic and clinical data at the time of TDM are listed in Table 10. Patients were at 
901 ± 870 days of therapy with ATV, mainly treated at the conventional ATV/r dosage 
300/100 mg qd (68%), given concomitantly with TDF-based ARV regimens (56%). Ninety-
two percent of them were Caucasians. Thirty-nine (16%) out of the 240 patients evaluated 
(28 on ATV 300/100 mg and 11 on ATV 400 mg) had detectable viral load at the time of 
TDM (median, interquartile range 2.36, 1.97–3.25 log cp/mL). 
Table 10. Main demographic, hematologic and biochemical characteristics of HIV-
positive patients receiving atazanavir as part of their ARV regimen 
Parameters All Patients (n=240) ATV/r  300/100 
(n=163) 
ATV 400 (n=77) 
Male gender % 68%  74%  56% 
Age, years 46±11  45±10  49±13 
Naïve, %  23%  29%  11% 
ATV therapy, days  901±870  846±886  1021±851 
HAART, %  56% TDF-based  60% TDF-based  47% TDF-based 
 24% ABC-based  24% ABC-based  22% ABC-based 
 10% RAL-based  7% RAL-based  18% RAL-based 
 10% others  9% others  13% others 
Weight, Kg  69±14  70±14  68±14 
Body mass index, Kg/m
2
  24±4  24±4  24±4 
Creatinine, mg/dL  0.9±0.4  0.9±0.3  0.9±0.7 
GGT, IU/L  72±114  85±134  47±48 
ALT, IU/L  47±49  49±53  42±40 
Total bilirubin, mg/dL  2.1±1.6  2.3±1.7  1.7±1.2 
Total cholesterol, mg/dL  187±46  191±48  178±39 
HDL cholesterol, mg/dL  50±29  50±33  49±18 
Triglycerides, mg/dL  167±124  179±132  143±104 
CD4, cells/mL  593±247  572±249  639±239 
Pts with VL>100 cp/mL, 
%  
12%  13%  11% 
HCV/HBV coinfection, %  34% 36% 26% 
        RAL: raltegravir; GGT: gamma-glutamyltransferase; ALT: alanine aminotransferase; HCV: hepatitis C 
virus; HBV: hepatitis B virus; VL: viral load 
 
b. Distribution of ATV plasma trough concentrations 
A wide distribution was observed in the ATV plasma trough concentrations, with me-
dian values of 546 [204–1030] ng/mL, resulting in a mean inter-patient variability of 110.3%. 
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Four percent of the determinations resulted <20 ng/mL. As expected, mean ATV plasma con-
centrations were higher in patients using RTV-boosted ATV than in patients using unboosted 
ATV (given at 400 qd or 200 bid) (650 [357–1204] vs. 238 [99–551] ng/mL, p<0.0001). 
As shown in Figure 11, a significant proportion of patients with ATV plasma trough 
concentrations out of the therapeutic drug window were identified. 43.9% of patients treated 
with ATV 300/100 qd had ATV concentrations exceeding the upper therapeutic threshold, 
whereas unboosted ATV 400 mg was associated with the highest proportion of values <150 
ng/mL (35.5%,Table 11). 
 
Figure 11. Box-plot of atazanavir (ATV) plasma trough concentrations clustered ac-
cording to drug dosage 
Dashed lines represent the upper and lower limits of the therapeutic window of ATV concentrations 
(150–800 ng/mL) 
 
Table 11. Distribution of atazanavir (ATV) plasma trough concentrations according to daily drug 
dosage 
 ATV ng/mLmedian 
[IQR] 
Samples < 
150 ng/mL 
Samples150–800 
ng/mL 
Samples 
>800 ng/mL 
All evaluations  
(n = 240)  
546 [204–1030]  21.2%  44.3%  34.4% 
ATV/r 300/100 mg qd 
(n = 164)  
650 [357–1204]  11.6%  44.5%  43.9% 
ATV 400 mg*  
(n = 76)  
238 [99–551]  35.5%  44.7%  19.8% 
*given either as 400 mg qd or 200 mg bid; IQR: interquartile range 
 
 
 
 
 
Experimental and Results 
59 
 
c. ATV plasma concentrations and hyperbilirubinemia 
One-hundred forty-seven (61%) out of the 240 HIV-positive patients enrolled in the 
present study experienced hyperbilirubinemia of grade ≥1. As shown in Figure 12, a signifi-
cant and direct association has been observed between the severity of hyperbilirubinemia and 
ATV plasma trough concentrations (ATV concentrations: 271 [77–555], 548 [206–902], 793 
[440–1164], 768 [494–1527] and 1491 [1122–1798] ng/mL in patients with grade 0, 1, 2, 3 
and 4 hyperbilirubinemia, respectively, with p<0.01 of grade 2, 3, and 4 vs. grade 0. The 
same trend was confirmed also when repeating the above mentioned comparisons stratifying 
data according to boosted or unboosted ATV intakers (Table 12). 
 
 
Figure 12. Box plot of ATV plasma trough concentrations clustered according to the 
grade of hyperbilirubinemia (scored as grade 0, 1, 2, 3 or 4 based on total bilirubin 
concentrations below 1.3 mg/dL, between 1.3–1.9, 1.9–3.1, 3.1–6.1, or above 6.1 
mg/dL, respectively).  
*p<0.01 vs grade 0. 
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Table 12. Atazanavir (ATV) plasma trough concentrations measured in patients that did or 
did not experienced drug-related adverse events 
Adverse event  N Overall patients N ATV/r 300/100 n ATV 400 
Hyperbilirubinemia       
- Grade 0  86 271 (77–555)  52  347 (121–785)  34  141 (56–293) 
- Grade 1  45 548 (206–902)  30  634 (355–962)  15  194 (106–358) 
- Grade 2  54 793 (440–1164)*  40  909 (586–1264)**  14  466(260–804)** 
- Grade 3 41 768 (494–1527)*  31  825 (531–1368)**  10  540(394–1979)* 
- Grade 4  7  1491 (1122–1798)*  6  1363 (1066–1693)**  1 1836 
Dyslipidemia  55 582 (266–1148)*  44 746 (305–1313)**  11 250 (106–486) 
Nephrolitiasis  11 1098 (631–1238)*  9 9 1098 (652–1285)**  2 742 (293–1191) 
Controls^  66 218 (77–541)  39  343 (125–810)  27 141 (50–259) 
Data were stratified also according to ritonavir use. 
^patients that did not develop ATV-related adverse events; 
 *p < 0.01 and 
**p < 0.05 vs. Controls 
 
d. ATV plasma concentrations and other drug-related adverse events 
Overall, 55 out of the 240 HIV-positive patients developed dyslipidemia, namely hy-
percholesterolemia (n = 26, mean increase 46±22%) or hypertriglyceridemia (n = 45, mean 
increase 114±76%). Patients with dyslipidemia had ATV concentrations significantly higher 
as compared with patients with no ATV-related complications (582 [266–1148] vs. 218 [77–
541] ng/mL, p<0.01). This was confirmed also when repeating the above mentioned compari-
sons according to RTV or not administration (Table 12). Moreover, in order to demonstrate a 
direct relationship between ATV concentrations and lipid increase, we attempted to correlate 
ATV concentrations with the magnitude of lipid levels increase as compared to baseline. Us-
ing this approach we found a direct association between ATV concentrations and the percent-
age increase in serum triglycerides levels (Figure 13). A similar, but not significant trend was 
also observed for cholesterol.  
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Figure 13. Box plot of ATV plasma trough concentrations clustered according to the 
magnitude of triglyceride concentrations increase as compared to values measured at 
the last visit before starting ATV 
*p<0.01 and **p<0.05 vs. patients experiencing ≤20% increase (first column from the left) 
 
At univariate analysis ATV concentrations (p<0.001), concomitant HAART (p = 
0.079), RTV use (p = 0.009) and patients’ gender (p = 0.046) were associated with the devel-
opment of dyslipidemia, while no association was found with other clinical covariates (Table 
13). In the multivariable regression analysis only ATV concentrations (p<0.01) and RTV use 
(p = 0.02) remained independently associated with dyslipidemia. 
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Table 13. Univariate and multivariate regression analysis of clinical, 
demographic and pharmacological covariates associated with the devel-
opment of atazanavir (ATV)-related dyslipidemia 
 Univariate Multivariate 
Variable  r-value  p-value  r- value  p-value 
Gender 0.14 0.046   
Age 0.04 0.502   
Body weight 0.04 0.469   
Serum creatinine 0.01 0.616   
ALT <0.01 0.276   
GGT 0.01 0.172   
HCV/HBV 
Coinfection  
0.01  0.873   
CD4 count  0.02  0.336   
Concomitant ARV 
drugs  
0.12  0.079   
Days of ATV thera-
py 
<0.01 0.980   
ATV concentrations 0.35 <0.001 0.33 <0.01 
Ritonavir use 0.18 0.009 0.18 0.02 
r-value: correlation coefficient; GGT: gamma-glutamyltransferase; ALT: alanine 
aminotransferase; HCV: hepatitis C virus; HBV: hepatitis B virus; ATV: atazanavir 
Eleven out of the 240 HIV-positive patients enrolled in the present study experienced 
episodes of nephrolitiasis indirectly attributed to ATV after having excluded other clinical 
conditions predisposing to kidney stones. As shown in Table 12 these patients were mainly 
treated with RTV (82%) and had ATV concentrations significantly higher as compared with 
patients with no ATV-related complications (1098 [631–1238 vs. 218 [77–541] ng/mL, 
p<0.01). Only one out of 240 patients experienced an episode of cholelithiasis 226 days after 
starting treatment with ATV (ATV plasma trough concentrations: 438 ng/mL). 
2.5. A case study on suspected pharmacokinetic interaction between 
raltegravir and the 3D regimen of ombitasvir, dasabuvir and 
paritaprevir/ritonavir in an HIV-HCV liver transplant recipient.  
After the introduction of the HAART, HIV infection is no longer considered an abso-
lute contraindication for solid organ transplantation in patients with end-stage liver disease 
[209,210]. However, recurrence of hepatitis C virus (HCV) infection after liver transplanta-
tion is frequent and may lead to allograft loss [211,212]. Thus, safe and effective treatment of 
HCV in the post-transplant setting is a mandatory task that needs to be addressed properly. 
The combination of ombitasvir, dasabuvir and paritaprevir/RTV (referred as 3D regimen) has 
been proven to be associated with high sustained virologic response in HIV-HCV co-infected 
patients [213,214] and optimal tolerability when co-administered with immunosuppressive 
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drugs in healthy volunteers [215]. Theoretically, 3D regimen has also a limited propensity to 
interact with RAL that is usually given to HIV-infected patients undergoing solid organ 
transplantation to limit drug to- drug interactions between HAART and immunosuppressive 
agents [216,217]. 
A 57-year-old HIV-infected patient received orthotopic liver transplantation in 2008 
for HCV and hepatocellular carcinoma. Post-transplant, he had recurrence of chronic infec-
tion with the HCV genotype 1a. He was on maintenance HAART with ABC, lamivudine and 
RAL since 2008 with an optimal virologic response (HIV RNA <37 cp/mL) and CD4 count 
of 272 cells/μL. Long-term immunosuppressive regimen was of 50 mg cyclosporine 
monotherapy twice daily with trough concentrations ranging from 80 to 140 ng/mL. On July 
2014, 3D treatment was started. His Child-Pugh class was B with a score of 8 with minimal 
alterations in serum transaminases (aspartate aminotransferase 93 IU/mL, alanine aminotrans-
ferase 38 IU/mL) and with surveillance abdominal imaging negative for the recurrence of 
hepatocellular carcinoma. In agreement with the available literature [215], the dose of cyclo-
sporine was initially reduced to 20 mg qd and subsequently increased up to 30 mg bid on the 
basis of trough drug concentrations. TDM of RAL plasma concentrations, performed by the 
collection of blood samples immediately before and at 1, 2, 3 and 4 h after the morning drug 
dose, was carried out before, during and at the end of 3D treatment (two assessments for each 
time period). RAL plasma concentration was determined by using validated HPLC-UV assay 
method (Section 3.1). RAL area under curve over 12 h (AUC0–12) was estimated using a 
previously validated algorithm [218]. As shown in Figure 14, a dramatic increase in the RAL 
AUC0–12 was observed during co-administration of the 3D regimen (from 8.68±4.48 to 
31.72±0.45 μgxh/mL; +265 %). No other drugs known to potentially interfere with RAL 
pharmacokinetics were given during the 3D treatment period. The patient did not experience 
alterations in serum transaminases or creatine phosphokinase levels and was able to complete 
the 6-month scheduled 3D therapy. At the conclusion of the antiviral treatment, the patient 
exhibited sustained viral clearance with tests negative for HCV RNA at week 12 post-
therapy. 
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Figure 14.Mean RAL AUC0–12 values measured before, during and at the end of the 
3D therapy (n = 2 for each observational period). Vertical bars represent the standard 
deviation 
Two RAL pharmacokinetic assessments performed 6 to 9 months later revealed a re-
duction in the RAL AUC0–12 (3.50±1.29 μgxh/mL). Worthy of mention, at the last available 
follow-up, HIV RNA was undetectable, serum transaminases were in the normal range and 
cyclosporine trough concentration was 115 ng/mL.  
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3.1. An HPLC-UV Method for the Simultaneous Quantification of Nine 
Antiretroviral Agents in the Plasma of HIV-Infected Patients 
a. Discussion 
In this part of the study we report the development and validation of an HPLC-UV as-
say to quantify simultaneously nine ARV compounds with accuracy and precision. This bio-
analytical method is now being successfully applied to measure ARV plasma concentrations 
for therapeutic purposes.  
Under our laboratory conditions all drugs including IS appeared to be stable when 
subjected to heat inactivation and freeze/thaw cycles, in comparison to freshly prepared con-
trols. Moreover, long-term stability data suggested that all analytes remained sufficiently sta-
ble under our current storage conditions (−20 0C). The stability of extracted samples at room 
temperature (24 
0
C) or within the auto-sampler (which is maintained at 10 
0
C) was found to 
be stable over the period of analysis.  This HPLC-UV SPE assay has a short run time of 25 
min per cycle with simple gradient making it suitable for a high-throughput TDM whereby 
large numbers of samples are processed quickly and efficiently. This is of high value in any 
clinical setting where laboratory analyses have to be optimized combining time-efficiency 
and reliability. 
Emergence of drug-resistant HIV-1 strains and problems of long-term tolerability of 
some anti-HIV compounds can jeopardise efficacy and acceptability of existing anti-HIV 
medications; Hence the need to develop new drugs. DTG and RPV are among the most recent 
and promising anti-HIV molecules. Both these drugs have been shown to be highly effective 
in multi treated patients and found to be well tolerated. DTG and, especially, RPV which is 
the substrate and inhibitor of P450 (CYP)3A4  have a high potential for interactions with oth-
er ARV agents , notably with PI and MVC . RGV and ETV also have a high potential for 
drug interactions, being substrates and inducers of CYP3A4[93]. Patients administered DTG 
and/or RPV are also given other ARV compounds; therefore, measurement of plasma con-
centrations of the different drugs associated in the same ARV regimen is necessary. Our 
method is of particular clinical value as it allows a quick and reliable assessment of the 
plasma level of these drugs, although the clinical usefulness of TDM of DTG and RPV and 
their interactions with other co-administered drugs still needs to be investigated further.  
Our assay method included widely prescribed PI’s, NNRTI’s and integrase inhibi-
tor’s. The choice for the limits of their ranges was based on the highest values reported in the 
clinical reports and PK studies. Reliability, costs, ruggedness, sensitivity and reproducibility 
are key points of measurement of drug plasma concentrations. Our assay, relying on SPE 
coupled with a high-sensitive Waters UV detector, was simple, reliable, sensitive, and less 
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expensive in terms of consumables and instrumentation when compared with other methods 
developed for LCMS or LC-MS/MS.  
The relative accuracy of all QC’s at three different concentration levels and intraday 
and interday precision supports both the accuracy and precision of our procedure. The choice 
of a specific wavelength for each drug (Table 2) was based on the need for adequate sensitiv-
ity and high specificity. An example is ETV and RPV for which quantification at 305 nm was 
chosen to ensure the absence of interferences and better sensitivity. The absence of interfer-
ing peaks, excluding the overlapping of DTG with RGV and EFV with LPV, allowed accu-
rate measurement of drugs plasma concentrations.  The Co-elution of DTG and RGV, occur-
ring with our method because of similar retention time, is not an issue as both drugs belong to 
the same class and hence are highly unlikely to be prescribed together. Co-elution of LPV 
with EFV can be tackle by running two different assays or by analysing either one of them in 
single assay.   
 
b. Conclusion  
The SPE and HPLC-UV methods described here allow accurate and reproducible 
simultaneous quantification of nine ARV agents in plasma by a single assay. Good extraction 
efficiency and low limit of quantification make this a suitable method for use in clinical trials 
and for TDM. This method has been successfully applied for our routine TDM studies in 
HIV-infected patients. 
3.2. Development and validation of electrospray ionization LC-
tandem mass assay for the simultaneous measurement of ten antiretrovi-
ral agents in human plasma samples 
a. Discussion 
In this part of the study we reported the development and validation of an electrospray 
ionization LC-tandem mass assay for the simultaneous measurement of ten ARV agents in 
human plasma samples. This bio-analytical method is now being successfully applied to 
measure ARV plasma concentrations for therapeutic purposes.  
Under our laboratory conditions all drugs including IS appeared to be stable when 
subjected to heat inactivation and freeze/thaw cycles, in comparison to freshly prepared con-
trols. Moreover, long-term stability data suggested that all analytes remained sufficiently sta-
ble under our current storage conditions (−20 0C). The stability of extracted samples at room 
temperature (24 
0
C) or within the auto-sampler (which is maintained at 10 
0
C) was found to 
be stable over the period of analysis.  This LC-MS/MS assay has a short run time of 8 min 
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per cycle with simple gradient making it suitable for a high-throughput TDM whereby large 
numbers of samples are processed quickly and efficiently. The assay showed excellent linear-
ity over the studied concentration ranges. The mean coefficient of determination (r
2
) of all 
calibration curves was more than 0.998. The % CV and accuracy of the LOQ, for each ARV 
drug, were within the limits of ± 20% and 80% to 120% respectively as recommended by the 
U.S. Food and Drug Administration guidelines. The results of assay precision and accuracy, 
assessed at 3 QC concentrations for all ARV agents are within the acceptable limits.  In terms 
of selectivity and specificity no significant interference with ARV’s concomitantly adminis-
tered to the patients was observed .This is of high value in any clinical setting where labora-
tory analyses have to be optimised combining time-efficiency and reliability. 
This LC-MS/MS method has been successfully applied for routine TDM in our labor-
atory. We determined trough plasma concentrations with the method reported here using 
samples from patients with HIV-1 treated with drugs mentioned in this method. 
 
b. Conclusion 
The development and validation of this assay were performed to quantify ATV, APV, 
EFV, IDV, MVC, NFV, NPV, RTG, RTV, SQV, for routine TDM in patients with HIV-1 
treated with multiple ARV regimens. The assay requires a small volume of plasma for analy-
sis (100 μL) and combines a short time of analysis of 8 minutes per sample, following quick 
and simple protein precipitation. 20 µL of each sample were injected onto the analytical col-
umn except 40 µL for EFV. In conclusion, a rapid, specific, and sensitive LC-MS/ MS meth-
od for the quantification of 10 currently approved ARV’s in human plasma was developed 
and has been successfully applied for routine TDM and pharmacokinetic studies in patients 
with HIV. 
3.3. A pharmacokinetic viewpoint on antiretrovirals dosing and possibil-
ity of dose reduction 
a. Discussion 
The large majority of patients treated with DRV, ETV and MVC had concentrations 
largely exceeding the minimum effective concentrations reported in the literature Figure 9. 
As no evidence is available to date on potential associations between plasma concentrations 
of DRV, ETV and MVC and drug-related toxicities, we were not able to estimate the per-
centage of patients potentially overexposed to these drugs. A very wide distribution in the 
measured RAL plasma trough concentrations (n 408) was observed [median, (interquartile 
range) concentrations: 338 (42 to 9814) ng/ml corresponding to an inter-patient coefficient of 
variation of 158.63 , with 17.1 % of samples below the tentative minimum effective concen-
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tration of 40 ng/ml [20]. No upper therapeutic threshold of RAL concentrations associated 
with drug tolerability is defined currently. 
A large percentage of patients treated with in label doses of LPV (34.4 % patients 
above 7000 ng/ml), ATV (45.1 % patients above 800 ng/ml), and NVP (35.1 % patients 
above 6000 ng/ml), were found to have trough concentrations largely exceeding the upper 
therapeutic threshold (Error! Reference source not found.), therefore patients potentially 
overexposed to ARV therapies and hence increased risk to drug-related toxicity. Indeed, evi-
dence is available showing that high concentrations of TDF, LPV, ATV, EFV and NVP cor-
related with treatment tolerability. It is more difficult to confirm this trend for novel drugs – 
namely DRV, ETV and MVC – simply because no clinical evidence is available to date cor-
relating their plasma concentrations with toxicity. Similarly, no conclusion can be drawn for 
RAL. As confirmed by this and our previous findings, trough concentrations of RAL were 
associated with a very wide interpatient variability [129]. In our clinical practice, we discour-
age monitoring RAL by measuring trough level because this concentration does not correlate 
with RAL area under the curve (AU0–12 h) [129]. Rather, we suggest considering limited 
sampling strategies on the basis of the collection of four to five plasma samples in the first 3–
4 h after drug administration to predict q.d. RAL exposure [218]. In the present study, we 
were not able to assess intrapatient variability because we considered only one sample per 
patient. However, emerging evidence is now available showing that intrapatient variability of 
RAL pharmacokinetics is much higher than PI’s and nonnucleoside reverse trascriptase in-
hibitors  [129,219–221]. 
 
b. Conclusion 
The main limitation of our investigation is represented by the lack of clinical infor-
mation on patients’ characteristics, their immune-virologic status, concomitant medications 
and treatment tolerability. Here, we would like just to give a picture of exposure of HIV-
infected patients to ARV treatments in a real-life scenario, providing a pharmacokinetic-
based rationale for TDM-guided dose reduction of current therapies. Further studies are 
needed to confirm our hypothesis with strong clinical endpoints. 
In conclusion, in this study, we document that a significant proportion of patients 
treated with some of the ARV’s at marketed doses had plasma concentrations exceeding the 
upper therapeutic threshold. Such selected patients, who might have the highest risk of expe-
riencing drug-related complications, may benefit from TDM-driven adjustments in ARV dos-
es with potential advantages in terms of costs and toxicity This approach, however, may be 
difficult to be applied in an era of fixed-dose regimens and fixed-dose combinations. Further 
studies are, therefore, needed to identify good candidates/drugs for TDM. 
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3.4. Metabolic and kidney disorders correlate with high atazanavir con-
centrations in HIV infected patients 
a. Discussion 
In this study, we document that a significant proportion of HIV-infected patients 
treated with ATV at the standard 300/100 mg qd dosage had plasma drug concentrations 
largely exceeding the upper therapeutic threshold, whereas nearly one third of patients treated 
with unboosted ATV had drug concentrations below 150 ng/mL, considered as the minimum 
concentration to be reached for the optimal management of patients on ATV-based ARV reg-
imens [183] . 
More than 60% of HIV-positive patients enrolled in the present study experienced 
hyperbilirubinemia of grade 1 or more, allowing us to deeply investigate the potential contri-
bution of ATV concentrations on this drug-related adverse event. In our study we firstly con-
firmed the previously reported relationship between ATV exposure and the increase in total 
bilirubin concentrations[183,206,207]. Moreover, we extended previous findings by docu-
menting a direct and linear correlation between ATV trough concentrations and the severity 
of hyperbilirubinemia. Interestingly, such relationship was established also when excluding 
patients homozygous for the UGT1A1*28, the genotype associated with a defect in the me-
tabolism of bilirubin[222,223]. Using this approach, we demonstrated that association of 
ATV exposure with hyperbilirubinemia still persisted also in patients with the favourable 
UGT genotype. Accordingly, it could be speculated that in these patients, lacking of an inher-
ited risk to experience the event, ATV-related hyperbilirubinemia might be eventually re-
versed by reducing ATV doses. 
The potential effect of ATV on lipid profile is still a matter of debate. Meta-analyses 
have reported that plasma lipid concentrations were lower with ATV/r than with other RTV-
boosted PI regimens [224] . Nevertheless, evidence is also available showing that ATV has a 
worst atherogenic lipid profile compared with NNRTI’s[198]. Our exploratory analyses 
study extended previous findings by documenting that dyslipidemia might be associated with 
ATV plasma trough concentrations. In order to demonstrate a direct relationship between 
ATV exposure and lipid increase, we correlated ATV concentrations with the magnitude of 
lipid levels increase as compared to baseline. Using this approach we found a linear and sig-
nificant association between ATV concentrations and the percentage increase in serum tri-
glycerides levels, but not for cholesterol, probably because of the less number of events and 
the narrow distribution in the percentage increased compared with triglyceride concentra-
tions. Among the different ATV-based regimens, lipid alterations were more frequently 
found in patients on ATV/r that in those given ATV alone [199] , suggesting a key role of 
RTV [225] . This has been fairly confirmed also by our study by documenting that: I) patients 
experiencing ATV-related complications were more frequently receiving RTV; II) the signif-
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icant association between RTV and ATV-related dyslipidemia was confirmed by multivariate 
analyses. In order to avoid the potential bias related to RTV use associated to the fact that a 
higher proportion of patients in the “adverse effect group” were treated with boosted ATV 
compared with control patients (those who did not experienced ATV-related complications), 
we repeated our comparisons stratifying data according to RTV boosted/unboosted intakers. 
Also using this approach, we documented that among patients given ATV/r 300/100, those 
experiencing dyslipidemia have significantly higher ATV concentrations compared with 
those not experiencing drug-related complications. A similar, but not significant, trend was 
found also in patients treated with ATV 400 mg. The small number of ATV unboosted 
intakers did not allow us to reach definitive conclusion on this topic. We are, however, confi-
dent that our preliminary findings could provide the rationale for ad-hoc prospective studies 
aimed at investigating the impact of ATV exposure on dyslipidemia in unboosted regimens. 
We also acknowledged that, as an important additional limitation, no information were avail-
able on RTV exposure, because RTV concentrations are not assessed in the routine manage-
ment of HIV patients. Accordingly, the potential contribution of RTV co-administration on 
episodes of dyslipidemia in patients treated with ATV cannot be completely ruled out. 
Cases of complicated and uncomplicated ATV-associated nephrolithiasis have been 
described, sometimes leading to obstructive uropathy and acute renal failure [226–229]. The 
association between exposure to ATV and increased incidence kidney stones has been subse-
quently confirmed also by epidemiological studies [230] . To the best of our knowledge, our 
is the first study showing that overexposure to ATV is associated also with increased risk of 
nephrolitiasis. It should be, however, acknowledged that as potential limitation of the present 
observation, the presence of ATV in the stones was not directly verified, and that episodes of 
drug-related nephrolitiasis were diagnosed indirectly after excluding the presence of oxalate 
or urate crystals in urinalysis and high value of serum uric acid. 
The potential association between exposure to ATV and increased risk to 
cholelithiasis is still a matter of debate , however Rakotondravelo and co worker have report-
ed 14 case of ATV releated cholelithiasis [231]. In our cohort, we found only one episode of 
cholelithiasis in a patient treated with ATV for less than one year. 
b. Conclusion 
In conclusion, in this study we documented that significant proportion of patients 
treated with conventional ATV dosages had plasma concentrations exceeding the upper ther-
apeutic threshold. A likely possibility is an inherited deficit in ATV clearance[232] and/or 
ATV metabolism; in particular, ATV is a dedicated CYP3A substrate, which includes 3A4 
and 3A5, two polymorphic genes [200–202]. The administration of unboosted ATV to 
healthy subjects carrying the defective CYP3A5*3 resulted in significantly higher ATV con-
centrations compared with values measured in patients expressing CYP3A5 [222]. Assuming 
that over 90% of patients in our study were Caucasians with a high prevalence of carriers of 
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CYP3A5 *3, it is likely that the observed overexposure to ATV concentrations is the result of 
excessively high dose of RTV-boosted ATV or of needless boosting with RTV. This is a first 
important conclusion of our study that raises concerns on the need of full dose of RTV-
boosted ATV in Caucasian patients and opens new questions about the ATV dosages that 
should considered correct (or in label and off label in Europe). This may be particularly rele-
vant in light of the recent findings showing that RTV may accumulate at intracellular level at 
higher degree than other PI’s providing additional antiviral activity and eventually allowing 
the use of reduced PI doses[233]. We also found that such patients have the highest risk of 
experiencing ATV-related complications and may benefit from TDM-driven adjustments in 
ATV dosage with potential advantages in terms of costs and toxicity. 
3.5. Suspected pharmacokinetic interaction between raltegravir and the 
3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-
HCV liver transplant recipient 
a. Discussion 
This study show that the 3D regimen of ombitasvir, dasabuvir and paritaprevir/RTV is 
safe and efficacious in HIV-HCV co-infected patients [213,214]. Studies in healthy volun-
teers have also provided indirect evidence that 3D regimen can be safely given to liver trans-
plant recipients provided that the doses of immunosuppressive agents are reduced and their 
concentrations strictly monitored[215]. However, no data are available to date on the use of 
the 3D regimen in HIV-HCV co-infected liver transplant recipients given RAL based 
HAART. Here, we confirm the optimal safety of this combination in our patient. At the same 
time, we observed a nearly 300 % increase in the RAL AUC0–12 during concomitant 3D 
treatment that returned to baseline values at the end antiviral therapy. Hence, it cannot be ex-
cluded that this increment might become clinically relevant in patients that are more prone to 
experience RAL-related hepatic or muscle toxicities[234] . In these circumstances, TDM-
guided early RAL dose adjustments during 3D therapy may improve the tolerability of pa-
tients to both HCV and HIV therapies. 
The mechanisms explaining this unanticipated drug-to drug interaction are unknown. 
A potential contribution of improved liver function and ability to eliminate RAL after clear-
ance of HCV is unlikely according to the recent results by Barau et al. [235]. We can specu-
late that the observed increase in RAL exposure might be due to UGT1A1 inhibition by 
paritaprevir/RTV, ombitasvir and/or dasabuvir, by an effect of 3D on transport proteins in-
volved in the disposition of RAL [236,237]. 
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b. Conclusion  
In conclusion, a threefold increase in RAL exposure in HIV-HCV co-infected liver 
transplant recipients treated with the 3D regimen for recurrent HCV infection was described. 
Such suspected interaction, which might be clinically relevant in selected patients, is easily 
manageable through TDM of RAL concentrations, eventually improving the safety of this 
drug. 
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% CV  Coefficient of variation  
3TC  lamivudine  
ABC   Abacavir 
APV  Amprenavir 
ARV  Antiretroviral 
ARV’s  Antiretrovirals 
ATV  Atazanavir 
b.i.d.  Twice (two times) a day 
Cmax  Maximum (or peak) serum concentration 
d4T  Stavudine  
ddI  Didanosine   
DLV  Delavirdine 
DRV  Darunavir 
DTV  Dolutegravir 
EFV  Efavirenz 
EI  Electron ionisation  
ETV  Etravirine 
ETV  Etravirine 
EVG  Elvitegravir 
FOS-APV Fosamprenavir 
FTC  Emtricitabine 
GC  Gas chromatography 
GC/MS Gas chromatography/ mass spectrophotometer 
HAART Highly active antiretroviral therapy 
HPLC  High performance thin layer chromatography 
IDV  Indinavir 
LC-MS/MS Liquid chromatography-tandem mass spectrophotometer 
LOQ  Limits of quantification 
LPV  Lopinavir 
MS  Mass spectrophotometer 
MS/MS Tandem mass spectrophotometer 
MVC  Maraviroc 
NFV  Nelfinavir  
NNRTI’s Non nucleoside reverse transcriptase inhibitors 
NRTI’s Nucleoside reverse transcriptase inhibitors 
NVP   Nevirapine 
PBMC  Peripheral blood mononuclear cells 
PDA  Photo diode array 
PI’s  Protease Inhibitors 
q.d.  Once (one time) a day  
QC’s  Quality controls 
RPV  Rilpivirine  
RTV  Ritonavir 
SQV  Saquinavir 
T-20  Enfuvirtide 
TDF  Tenofovir 
TDM  Therapeutic drug monitoring  
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TPV  Tipranavir  
UPLC  Ultra performance liquid chromatography  
UV  Ultra violet 
ZDV  Zidovudine 
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